<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04493684</url>
  </required_header>
  <id_info>
    <org_study_id>212548</org_study_id>
    <nct_id>NCT04493684</nct_id>
  </id_info>
  <brief_title>GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers</brief_title>
  <official_title>A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3739937 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, double-blind (sponsor-unblinded), randomized, placebo-controlled,&#xD;
      single- and repeat-dose escalation study including a weekly oral dose (MAD) cohort and a&#xD;
      relative bioavailability (RBA) and food effect (FE) cohort to investigate the safety,&#xD;
      tolerability and PK of VH3739937 in healthy participants. This is a three part study. Part 1&#xD;
      and Part 2 is designed to gain information on the safety, tolerability, and pharmacokinetic&#xD;
      (PK) properties of GSK3739937 when administered as powder-in-a-bottle (PiB). Part 3 will&#xD;
      evaluate the RBA of the GSK3739937 PiB and GSK3739937 Tablet and the safety, tolerability and&#xD;
      PK parameters of the tablet formulation when administered under fasting and fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 is a single ascending dose study, Part 2 is multiple ascending dose study while Part 3 is a 3-period crossover design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double-blind study with participants and the site-staff blinded and sponsor unblended. Part 3 of the study will be open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 - Number of Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 27 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/Standard of care (SOC) to prevent one of the other outcomes mentioned before.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 - Number of Any AEs and SAEs</measure>
    <time_frame>Up to 5 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Number of Any AEs and SAEs</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Hematology Parameters - Erythrocytes Count</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameters - Erythrocytes Count</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameters - Erythrocytes Count</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Hematology Parameters - Erythrocytes Count</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Mean Corpuscular Hemoglobin (MCH). Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Mean Corpuscular Hemoglobin (MCH). Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Hematology Parameter - Hematocrit</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Hematocrit</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Hematocrit</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Hematology Parameter - Hematocrit</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Hematology Parameter - Reticulocytes</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Reticulocytes</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Reticulocytes</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Hematology Parameter - Reticulocytes</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Clinical Chemistry Parameter - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK)</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - ALT, AST, ALP and Serum CPK</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter -ALT, AST, ALP and Serum CPK</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Clinical Chemistry Parameter - ALT, AST, ALP and CPK</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen, Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, Triglycerides</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides Edit Properties | Duplicate Measure</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Clinical Chemistry Parameter - Total Protein</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 - (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - Total Protein</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter - Total Protein</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Clinical Chemistry Parameter - Total Protein</measure>
    <time_frame>Baseline (Day -1) and Day 6</time_frame>
    <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Number of Participants With Abnormal Urinalysis Parameters</measure>
    <time_frame>Up to 27 weeks</time_frame>
    <description>Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 - Number of Participants With Abnormal Urinalysis Parameters</measure>
    <time_frame>Up to 5 weeks</time_frame>
    <description>Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Number of Participants With Abnormal Urinalysis Parameters</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
    <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
    <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Vital Signs - Pulse Rate</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
    <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Pulse Rate</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Pulse Rate</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Vital Signs - Pulse Rate</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
    <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Vital Signs - Body Temperature</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
    <description>Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Body Temperature</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Body Temperature</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Vital Signs - Body Temperature</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
    <description>Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Change From Baseline in Vital Signs - Respiratory Rate</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
    <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Respiratory Rate</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
    <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Respiratory Rate</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
    <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Change From Baseline in Vital Signs - Respiratory Rate</measure>
    <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
    <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Number of Participants With Worst Case Post-Baseline Electrocardiogram (ECG) Findings</measure>
    <time_frame>Up to 27 weeks</time_frame>
    <description>Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 - Number of Participants With Worst Case Post-Baseline ECG Findings</measure>
    <time_frame>Up to 5 weeks</time_frame>
    <description>Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Number of Participants With Worst Case Post-Baseline ECG Findings</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Area Under the Plasma Concentration Time Curve (AUC) From Zero to 24 Hours (AUC[0-24]) of GSK3739937</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 12, 16 and 24 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Maximum Observed Concentration (Cmax) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - AUC(0-24) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12 and 24 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - AUC From Zero (Pre-dose) to Time of the Last Quantifiable Concentration (t) (AUC [0-t]) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - AUC(0-inf) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - Apparent Terminal Phase Half-life (T1/2) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - Apparent Oral Clearance (CL/F) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - Cmax of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - Concentration of GSK3739937 at 24 Hours (C24) of GSK3739937</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 12, 16 and 24 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - Last Quantifiable Concentration (Clast) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2 ) - Time of Occurrence of Cmax (Tmax) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - Lag Time (Tlag) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Cohort 1 and 2) - Time to Reach Clast (Tlast) of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period.</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3, 4 and 5) - AUC (0-24) of GSK3739937 on Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3, 4 and 5) - Cmax of GSK3739937 on Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3, 4 and 5) - C24 of GSK3739937 on Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3, 4 and 5) - Tmax of GSK3739937 on Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3, 4 and 5) - Tlag of GSK3739937 on Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - Tmax of GSK3739937 on Day 14</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - Cmax of GSK3739937 on Day 14</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - AUC From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3739937 on Day 14</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - Plasma Trough Concentration (Ctau) of GSK3739937 on Day 14</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - T1/2 of GSK3739937 on Day 14</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - CL/F of GSK3739937 on Day 14</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - Tmax of GSK3739937 on Day 18</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - Cmax of GSK3739937 on Day 18</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - AUC From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) on Day 18</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - Plasma Trough Concentration (Ctau) of GSK3739937 on Day 18</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - T1/2 of GSK3739937 on Day 18</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - CL/F of GSK3739937 on Day 18</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - AUC From Zero to 168 Hours (AUC[0-168]) of GSK3739937 From Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and up to 168 hours post-dose from Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Cmax of GSK3739937 on Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Concentration of GSK3739937 at 168 Hours (C168) From Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and up to 168 hours post-dose from Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Tmax of GSK3739937 on Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Tlag of GSK3739937 on Day 1</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6 ) - AUC(0-t) of GSK3739937 on Day 15</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Cmax of GSK3739937 on Day 15</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Ctau of GSK3739937 on Day 15</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Tmax of GSK3739937 on Day 15</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - T1/2 of GSK3739937 on Day 15</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - CL/F of GSK3739937 on Day 15</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 (Cohort 7) - C24 of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 (Cohort 7) Clast of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 (Cohort 7) - Tmax of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 (Cohort 7) - Tlag of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 (Cohort 7) - Tlast of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 (Cohort 7) - T1/2 of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 (Cohort 7) - CL/F of GSK3739937</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 - Dose Proportionality of GSK3739937 for Dose Levels 30 mg to 800 mg Using AUC(0-infinity) After Single Dose Administration of GSK3739937</measure>
    <time_frame>Up to day 16</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 - Dose Proportionality of GSK3739937 for Dose Levels 10 mg to 800 mg Using Cmax After Single Dose Administration of GSK3739937</measure>
    <time_frame>Up to day 16</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 10 mg, 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using AUC(0-24) After Repeated Dose Administration of GSK3739937</measure>
    <time_frame>Up to day 33</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using Cmax After Repeated Dose Administration of GSK3739937</measure>
    <time_frame>Up to day 33</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using Ctau After Repeated Dose Administration of GSK3739937</measure>
    <time_frame>Up to day 33</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 14</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 AUC(0-tau) / day 1 AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 18</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 18 AUC(0-tau) / day 1 AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 AUC(0-tau) / day 1 AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - Accumulation Ratio of Cmax (R [CMAX])</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 14</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 Cmax / day 1 Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - Accumulation Ratio of Cmax (R [CMAX])</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 18</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Actual measure type is Ratio. Accumulation ratio calculated as the ratio of day 18 Cmax / day 1 Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Accumulation Ratio of Cmax (R [CMAX])</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 Cmax / day 1 Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - Accumulation Ratio of C(Tau) (R[CTAU])</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 14</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 C(Tau) / day 1 C(Tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - Accumulation Ratio of C(Tau) (R[CTAU])</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 18</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 18 C(Tau) / day 1 C(Tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 6) - Accumulation Ratio of C(Tau) (R[CTAU])</measure>
    <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 C(Tau) / day 1 C(Tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 3 and 4) - Pre-dose Concentration of GSK3739937</measure>
    <time_frame>Up to day 15</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. For Part 2 cohorts 3 and 4, steady-state GSK3739937 concentrations was assessed by estimating the slope of concentrations on pre-dose assessments on Days 2-14 (Part 2 cohort 3 and 4) and the day 15 (24-hr post-dose relative to dosing on day 14). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Cohort 5) - Pre-dose Concentration of GSK3739937</measure>
    <time_frame>Up to day 19</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. For Part 2 cohort 5, steady state GSK3739937 concentrations was assessed by estimating the slope of the concentrations of pre-dose assessments on Days 2-18 and the day 19 (24-hr post-dose relative to dosing on day 18). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Part 1: Cohort 1: Participants receiving GSK3739937</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 cohort 1 may contain up to 4 escalating doses (Period 1- 10 milligram [mg], Period 2- 80 mg, and Period 3- 320 mg, Period 4- 800 mg) of GSK3739937.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 1: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this cohort, participants will be randomized to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 2: Participants receiving GSK3739937</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 cohort 2 may contain up to 3 escalating doses ( Period 1- 30 mg, Period 2- 160 mg, and Period 3- 640 mg) of GSK3739937.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 2: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this cohort, participants will be randomized to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 3: Participants receiving GSK3739937</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 25 mg GSK3739937 for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 3: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 4: Participants receiving GSK3739937</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 50 mg GSK3739937 for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 4: Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 5: Participants receiving GSK3739937</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 100 mg GSK3739937 for 18 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 5: Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 18 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 6: Participants receiving GSK3739937</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 7 participants will be randomized to receive three 500 mg doses of GSK3739937 administered at once weekly intervals over two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 6: Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 3 participants will be randomized to receive three doses of placebo administered at once weekly intervals over two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Cohort 7: Participants receiving treatment sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 1; Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 2; and Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Cohort 7: Participants receiving treatment sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 1; Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 2; and Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Cohort 7: Participants receiving treatment sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 1; Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 2; and Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3739937 (PIB)</intervention_name>
    <description>GSK3739937 will be administered as oral suspension.</description>
    <arm_group_label>Part 1: Cohort 1: Participants receiving GSK3739937</arm_group_label>
    <arm_group_label>Part 1: Cohort 2: Participants receiving GSK3739937</arm_group_label>
    <arm_group_label>Part 2: Cohort 3: Participants receiving GSK3739937</arm_group_label>
    <arm_group_label>Part 2: Cohort 4: Participants receiving GSK3739937</arm_group_label>
    <arm_group_label>Part 2: Cohort 5: Participants receiving GSK3739937</arm_group_label>
    <arm_group_label>Part 2: Cohort 6: Participants receiving GSK3739937</arm_group_label>
    <arm_group_label>Part 3: Cohort 7: Participants receiving treatment sequence ABC</arm_group_label>
    <arm_group_label>Part 3: Cohort 7: Participants receiving treatment sequence BCA</arm_group_label>
    <arm_group_label>Part 3: Cohort 7: Participants receiving treatment sequence CAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given orally during each dosing day.</description>
    <arm_group_label>Part 1: Cohort 1: Participants receiving Placebo</arm_group_label>
    <arm_group_label>Part 1: Cohort 2: Participants receiving Placebo</arm_group_label>
    <arm_group_label>Part 2: Cohort 3: Participants receiving Placebo</arm_group_label>
    <arm_group_label>Part 2: Cohort 4: Participants receiving Placebo</arm_group_label>
    <arm_group_label>Part 2: Cohort 5: Participants receiving placebo</arm_group_label>
    <arm_group_label>Part 2: Cohort 6: Participants receiving placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3739937 (Tablet)</intervention_name>
    <description>GSK3739937 Tablet will be administered via oral route.</description>
    <arm_group_label>Part 3: Cohort 7: Participants receiving treatment sequence ABC</arm_group_label>
    <arm_group_label>Part 3: Cohort 7: Participants receiving treatment sequence BCA</arm_group_label>
    <arm_group_label>Part 3: Cohort 7: Participants receiving treatment sequence CAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 55 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by the investigator or medically&#xD;
             qualified designee based on a medical evaluation including medical history, physical&#xD;
             examination, laboratory tests, and cardiac monitoring (history and ECG).&#xD;
&#xD;
          -  Participants who are negative on two consecutive tests for severe acute respiratory&#xD;
             syndrome coronavirus-2 (SARs-CoV-2), performed at Screening and on admission and&#xD;
             (re-)admission to the Phase I unit, using an approved molecular test polymerase chain&#xD;
             reaction (PCR).&#xD;
&#xD;
          -  Participants who are able to understand and comply with protocol requirements and&#xD;
             timetables, instructions, and protocol-stated restrictions.&#xD;
&#xD;
          -  Body weight &gt;=50.0 kilograms (kg) (110 pound [lbs]) for men and &gt;=45.0 kg (99 lbs) for&#xD;
             women and body mass index within the range 18.5 to 32.0 kilogram per square meter&#xD;
             (kg/m^2).&#xD;
&#xD;
          -  Male participants are eligible to participate if they agree to use contraceptive&#xD;
             methods&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and is not a woman of childbearing potential (WOCBP). - Capable of&#xD;
             giving signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs and symptoms which in the opinion of the investigator are suggestive of&#xD;
             coronavirus disease 2019 (COVID-19) (i.e. fever, cough etc) within 14 days of&#xD;
             inpatient admission.&#xD;
&#xD;
          -  Contact with known COVID-19 positive persons in the 14 days prior to inpatient&#xD;
             admission.&#xD;
&#xD;
          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             endocrine, hematological, or neurological disorders capable of significantly altering&#xD;
             the absorption, distribution, metabolism, or elimination of drugs; constituting a risk&#xD;
             when taking the study intervention or interfering with the interpretation of data.&#xD;
&#xD;
          -  Pre-existing clinically relevant, in the opinion of the principal investigator (PI),&#xD;
             gastro-intestinal pathology or diagnosis - e.g. irritable bowel syndrome, inflammatory&#xD;
             bowel disease, and/or significant baseline signs and symptoms.&#xD;
&#xD;
          -  Medical history of cardiac arrhythmias or cardiac disease or a family and personal&#xD;
             history of long QT syndrome.&#xD;
&#xD;
          -  Any known or suspected pre-existing psychiatric condition&#xD;
&#xD;
          -  Any positive (abnormal) response confirmed by the investigator or clinician (or&#xD;
             qualified designee) administered Columbia Suicide Severity Rating Scale (CSSRS) at&#xD;
             screening .&#xD;
&#xD;
          -  Any other clinical condition (including but not limited to active substance use) or&#xD;
             prior therapy that, in the opinion of the Investigator, would make the participant&#xD;
             unsuitable for the study; unable to comply with dosing requirements; or unable to&#xD;
             comply with study visits; or a condition that could affect the absorption,&#xD;
             distribution, metabolism or excretion of the drug.&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;90 milliliters/minute (mL/min) or serum&#xD;
             creatinine &gt;1.1 x upper limit of normal (ULN).&#xD;
&#xD;
          -  Hemoglobin &lt;12.5 grams/deciliter (g/dL) for men and &lt;11 g/dL for women.&#xD;
&#xD;
          -  ALT or AST &gt;1.1x ULN.&#xD;
&#xD;
          -  Bilirubin &gt;1.1 x ULN (isolated bilirubin &gt;1.1 x ULN is acceptable if bilirubin is&#xD;
             fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones)&#xD;
&#xD;
          -  Any significant arrhythmia or ECG finding (e.g., prior myocardial infarction in the&#xD;
             past 3 months (does not include ST segment changes associated with repolarization),&#xD;
             symptomatic bradycardia, non-sustained or sustained atrial arrhythmias, non-sustained&#xD;
             or sustained ventricular tachycardia (&gt;=3 consecutive ventricular ectopic beats),&#xD;
             second-degree atrioventricular (AV) block Mobitz Type II, third-degree&#xD;
             atrioventricular block, complete heart block, or conduction abnormality (including but&#xD;
             not specific to left or right complete bundle branch; AV block [2nd degree or higher];&#xD;
             Wolff-Parkinson-White [WPW] syndrome), Sinus Pauses &gt; 3 seconds, which, in the opinion&#xD;
             of the investigator or ViiV Healthcare (VH)/ GlaxoSmithKline (GSK) Medical Monitor,&#xD;
             will interfere with the safety for the individual participant.&#xD;
&#xD;
          -  Exclusion criteria for Screening ECG. Heart rate &lt;45 or &gt;100 beats per minute (bpm)&#xD;
             for males and &lt;50 or &gt;100 bpm for females; PR interval &lt;120 or &gt;220 millisecond&#xD;
             (msec); QRS duration &lt;70 or &gt;120 msec; the Fridericia's QT correction formula (QTcF)&#xD;
             interval &gt;450 msec.&#xD;
&#xD;
          -  Past or intended use of over-the-counter or prescription medication [including&#xD;
             cytochrome p450 enzyme inducers or inhibitors, vitamins, herbal and dietary&#xD;
             supplements ] within 7 days (or 14 days if the drug is a potential enzyme inducer) or&#xD;
             5 half-lives (whichever is longer) prior to dosing and for the duration of the study,&#xD;
             unless in the opinion of the Investigator and Sponsor, the medication will not&#xD;
             interfere with the study medications, procedures, or compromise participant safety.&#xD;
&#xD;
          -  Unwillingness to abstain from ingestion of any food or drink containing grapefruit and&#xD;
             grapefruit juice, Seville oranges, blood oranges, or pomelos within 7 days prior to&#xD;
             the first dose of study treatments or until the end of the study.&#xD;
&#xD;
          -  Participation in the study would result in loss of blood or blood products in excess&#xD;
             of 500 mL within 56 days&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months prior to the first&#xD;
             dosing day&#xD;
&#xD;
          -  Current enrolment or past participation within the last 30 days, 5 half-lives or twice&#xD;
             the duration of the biological effect of the investigational product (whichever is&#xD;
             longer) before signing of consent in this or any other clinical study involving an&#xD;
             investigational study intervention or any other type of medical research&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen (HBsAg) at screening or within 3 months prior&#xD;
             to first dose of study intervention&#xD;
&#xD;
          -  Positive Hepatitis C antibody test result at screening or within 3 months prior to&#xD;
             first dose of study intervention.&#xD;
&#xD;
          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3&#xD;
             months prior to first dose of study intervention&#xD;
&#xD;
          -  Positive pre-study drug/alcohol screen&#xD;
&#xD;
          -  Positive HIV antibody/antigen test&#xD;
&#xD;
          -  Regular use of known drugs of abuse&#xD;
&#xD;
          -  Regular alcohol consumption within 6 months prior to the study defined as: An average&#xD;
             weekly intake of &gt;14 units for males or &gt;7 units for females.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products (e.g. nicotine patches or vaporizing devices) within 6&#xD;
             months prior to screening and at admission.&#xD;
&#xD;
          -  Sensitivity to any of the study interventions, or components thereof, or drug or other&#xD;
             allergy that, in the opinion of the investigator or medical monitor, contraindicates&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <results_first_submitted>August 29, 2022</results_first_submitted>
  <results_first_submitted_qc>August 20, 2023</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2023</results_first_posted>
  <last_update_submitted>August 20, 2023</last_update_submitted>
  <last_update_submitted_qc>August 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>First-time-in-human</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04493684/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 21, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04493684/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study includes 3 parts. In part 1, 34 participants were randomized. In part 2, 40 participants were randomized. In part 3, 17 participants were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1 (Cohort 1) - Single Dose (SD) Placebo (PBO)/GSK3739937 SD 80 mg/GSK3739937 SD 320 mg</title>
          <description>Participants received single oral dose of placebo as suspension in Treatment Period 1, followed by single oral dose of 80 milligrams (mg) of GSK3739937 in Treatment Period 2, and followed by single oral dose of 320 mg of GSK3739937 in Treatment Period 3.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 (Cohort 1) - GSK3739937 SD 10 mg/ SD PBO/ GSK3739937 SD 320 mg</title>
          <description>Participants received single oral dose of 10 mg of GSK3739937 as suspension in Treatment Period 1, followed by single oral dose of placebo as suspension in Treatment Period 2, and followed by single oral dose of 320 mg of GSK3739937 as suspension in Treatment Period 3.</description>
        </group>
        <group group_id="P3">
          <title>Part 1 (Cohort 1) - GSK3739937 SD 10 mg/ GSK3739937 SD 80 mg/SD PBO</title>
          <description>Participants received single oral dose of 10 mg of GSK3739937 as suspension in Treatment Period 1, followed by single oral dose of 80 mg of GSK3739937 as suspension in Treatment Period 2, and followed by single oral dose of placebo as suspension in Treatment Period 3.</description>
        </group>
        <group group_id="P4">
          <title>Part 1 (Cohort 1) - GSK3739937 SD 800 mg</title>
          <description>Participants received single oral dose of 800 mg of GSK3739937 as suspension in Treatment Period 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 1 (Cohort 1) - SD PBO</title>
          <description>Participants received single oral dose of Placebo in Treatment Period 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 1 (Cohort 2) - SD PBO/ GSK3739937 SD 160 mg/ GSK3739937 SD 640 mg</title>
          <description>Participants received single oral dose of Placebo as suspension in Treatment Period 1, followed by single oral dose of 160 mg of GSK3739937 as suspension in Treatment Period 2, and followed by single oral dose of 640 mg of GSK3739937 as suspension Treatment in Period 3.</description>
        </group>
        <group group_id="P7">
          <title>Part 1 (Cohort 2) - GSK3739937 SD 30mg/ SD PBO/ GSK3739937 SD 640mg</title>
          <description>Participants received single oral dose of 30 mg of GSK3739937 as suspension in Treatment Period 1, followed by single oral dose of Placebo as suspension in Treatment Period 2, and followed by single oral dose of 640 mg of GSK3739937 as suspension in Treatment Period 3.</description>
        </group>
        <group group_id="P8">
          <title>Part 1 (Cohort 2) - GSK3739937 SD 30 mg/ GSK3739937 SD 160 mg/SD PBO</title>
          <description>Participants received single oral dose of 30 mg of GSK3739937 as suspension in Treatment Period 1, followed by single oral dose of 160 mg of GSK3739937 in Period 2, and followed by single oral dose of Placebo in Period 3.</description>
        </group>
        <group group_id="P9">
          <title>Part 2 - Once Daily (QD) PBO</title>
          <description>Participants received once daily oral doses of Placebo as suspension for 14 days in Treatment Period 1.</description>
        </group>
        <group group_id="P10">
          <title>Part 2 (Cohort 3) - GSK3739937 QD 25 mg</title>
          <description>Participants received once daily oral doses of 25 mg of GSK3739937 as suspension for 14 days in Treatment Period 1.</description>
        </group>
        <group group_id="P11">
          <title>Part 2 (Cohort 4) - GSK3739937 QD 50 mg</title>
          <description>Participants received once daily oral doses of 50 mg of GSK3739937 as suspension for 14 days in Treatment Period 1.</description>
        </group>
        <group group_id="P12">
          <title>Part 2 (Cohort 5) - GSK3739937 QD 100 mg</title>
          <description>Participants received once daily oral doses of 100 mg of GSK3739937 as suspension for 18 days in Treatment Period 1.</description>
        </group>
        <group group_id="P13">
          <title>Part 2 - Once Weekly (QW) PBO</title>
          <description>Participants received once weekly oral doses of Placebo as suspension for over 3 weeks in Treatment Period 1.</description>
        </group>
        <group group_id="P14">
          <title>Part 2 (Cohort 6) - GSK3739937 QW 500 mg</title>
          <description>Participants received once weekly oral doses of 500 mg of GSK3739937 as suspension for over 3 weeks in Treatment Period 1.</description>
        </group>
        <group group_id="P15">
          <title>Part 3 (Cohort 7) - GSK3739937 PiB Fed/ GSK3739937 Tablet Fed/ GSK3739937 Tablet Fasted</title>
          <description>Participants received single dose of 100 mg of powder in bottle (PiB) as oral suspension under moderate fed conditions in Treatment Period 1, followed by single oral dose of 100 mg of GSK3739937 tablet under moderate fed conditions in Treatment Period 2 and followed by single dose of 100 mg of GSK3739937 tablet under fasted conditions in Treatment Period 3.</description>
        </group>
        <group group_id="P16">
          <title>Part 3 (Cohort 7) - GSK3739937 Tablet Fed/ GSK3739937 Tablet Fasted/ GSK3739937 PiB Fed</title>
          <description>Participants received single oral dose of 100 mg of GSK3739937 tablet under moderate fed conditions in Treatment Period 1, followed by single oral dose of 100 mg GSK3739937 tablet under fasted conditions in Treatment Period 2 and followed by single dose of 100 mg PiB as oral suspension under moderate fed conditions in Treatment Period 3.</description>
        </group>
        <group group_id="P17">
          <title>Part 3 (Cohort 7) - GSK3739937 Tablet Fasted/ GSK3739937 PiB Fed/ GSK3739937 Tablet Fed</title>
          <description>Participants received single oral dose of 100 mg of GSK3739937 tablet under fasted condition in Treatment Period 1, followed by single oral dose of 100 mg PiB as oral suspension under moderate fed conditions in Treatment Period 2 and followed by single oral dose of 100 mg GSK3739937 tablet under fed conditions in Treatment Period 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1:Treatment Period 1-Up to 9 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1:Treatment Period 2-Up to 9 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4">2 additional participants were enrolled and dosed.</participants>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3">1 additional participant was enrolled and dosed.</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3">1 additional participant was enrolled and dosed.</participants>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1:Treatment Period 3-Up to 9 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4">1 additional participant was enrolled and dosed.</participants>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4">1 additional participant was enrolled and dosed.</participants>
                <participants group_id="P7" count="3">1 additional participant was enrolled and dosed.</participants>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2:Treatment Period 1-Up to 5 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 3:Treatment Period 1-Up to 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="5"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 3:Treatment Period 2-Up to 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="5"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 3:Treatment Period 3-Up to 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1 (Cohort 1) - Single Dose (SD) Placebo (PBO)/GSK3739937 SD 80 mg/GSK3739937 SD 320 mg</title>
          <description>Participants received single oral dose of placebo as suspension in Treatment Period 1, followed by single oral dose of 80 milligrams (mg) of GSK3739937 in Treatment Period 2, and followed by single oral dose of 320 mg of GSK3739937 in Treatment Period 3.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 (Cohort 1) - GSK3739937 SD 10 mg/ SD PBO/ GSK3739937 SD 320 mg</title>
          <description>Participants received single oral dose of 10 mg of GSK3739937 as suspension in Treatment Period 1, followed by single oral dose of placebo as suspension in Treatment Period 2, and followed by single oral dose of 320 mg of GSK3739937 as suspension in Treatment Period 3.</description>
        </group>
        <group group_id="B3">
          <title>Part 1 (Cohort 1) - GSK3739937 SD 10 mg/ GSK3739937 SD 80 mg/SD PBO</title>
          <description>Participants received single oral dose of 10 mg of GSK3739937 as suspension in Treatment Period 1, followed by single oral dose of 80 mg of GSK3739937 as suspension in Treatment Period 2, and followed by single oral dose of placebo as suspension in Treatment Period 3.</description>
        </group>
        <group group_id="B4">
          <title>Part 1 (Cohort 1) - GSK3739937 SD 800 mg</title>
          <description>Participants received single oral dose of 800 mg of GSK3739937 as suspension in Treatment Period 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 1 (Cohort 1) - SD PBO</title>
          <description>Participants received single oral dose of Placebo in Treatment Period 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 1 (Cohort 2) - SD PBO/ GSK3739937 SD 160 mg/ GSK3739937 SD 640 mg</title>
          <description>Participants received single oral dose of Placebo as suspension in Treatment Period 1, followed by single oral dose of 160 mg of GSK3739937 as suspension in Treatment Period 2, and followed by single oral dose of 640 mg of GSK3739937 as suspension Treatment in Period 3.</description>
        </group>
        <group group_id="B7">
          <title>Part 1 (Cohort 2) - GSK3739937 SD 30mg/ SD PBO/ GSK3739937 SD 640mg</title>
          <description>Participants received single oral dose of 30 mg of GSK3739937 as suspension in Treatment Period 1, followed by single oral dose of Placebo as suspension in Treatment Period 2, and followed by single oral dose of 640 mg of GSK3739937 as suspension in Treatment Period 3.</description>
        </group>
        <group group_id="B8">
          <title>Part 1 (Cohort 2) - GSK3739937 SD 30 mg/ GSK3739937 SD 160 mg/SD PBO</title>
          <description>Participants received single oral dose of 30 mg of GSK3739937 as suspension in Treatment Period 1, followed by single oral dose of 160 mg of GSK3739937 in Period 2, and followed by single oral dose of Placebo in Period 3.</description>
        </group>
        <group group_id="B9">
          <title>Part 2 - Once Daily (QD) PBO</title>
          <description>Participants received once daily oral doses of Placebo as suspension for 14 days in Treatment Period 1.</description>
        </group>
        <group group_id="B10">
          <title>Part 2 (Cohort 3) - GSK3739937 QD 25 mg</title>
          <description>Participants received once daily oral doses of 25 mg of GSK3739937 as suspension for 14 days in Treatment Period 1.</description>
        </group>
        <group group_id="B11">
          <title>Part 2 (Cohort 4) - GSK3739937 QD 50 mg</title>
          <description>Participants received once daily oral doses of 50 mg of GSK3739937 as suspension for 14 days in Treatment Period 1.</description>
        </group>
        <group group_id="B12">
          <title>Part 2 (Cohort 5) - GSK3739937 QD 100 mg</title>
          <description>Participants received once daily oral doses of 100 mg of GSK3739937 as suspension for 18 days in Treatment Period 1.</description>
        </group>
        <group group_id="B13">
          <title>Part 2 - Once Weekly (QW) PBO</title>
          <description>Participants received once weekly oral doses of Placebo as suspension for over 3 weeks in Treatment Period 1.</description>
        </group>
        <group group_id="B14">
          <title>Part 2 (Cohort 6) - GSK3739937 QW 500 mg</title>
          <description>Participants received once weekly oral doses of 500 mg of GSK3739937 as suspension for over 3 weeks in Treatment Period 1.</description>
        </group>
        <group group_id="B15">
          <title>Part 3 (Cohort 7) - GSK3739937 PiB Fed/ GSK3739937 Tablet Fed/ GSK3739937 Tablet Fasted</title>
          <description>Participants received single dose of 100 mg of powder in bottle (PiB) as oral suspension under moderate fed conditions in Treatment Period 1, followed by single oral dose of 100 mg of GSK3739937 tablet under moderate fed conditions in Treatment Period 2 and followed by single dose of 100 mg of GSK3739937 tablet under fasted conditions in Treatment Period 3.</description>
        </group>
        <group group_id="B16">
          <title>Part 3 (Cohort 7) - GSK3739937 Tablet Fed/ GSK3739937 Tablet Fasted/ GSK3739937 PiB Fed</title>
          <description>Participants received single oral dose of 100 mg of GSK3739937 tablet under moderate fed conditions in Treatment Period 1, followed by single oral dose of 100 mg GSK3739937 tablet under fasted conditions in Treatment Period 2 and followed by single dose of 100 mg PiB as oral suspension under moderate fed conditions in Treatment Period 3.</description>
        </group>
        <group group_id="B17">
          <title>Part 3 (Cohort 7) - GSK3739937 Tablet Fasted/ GSK3739937 PiB Fed/ GSK3739937 Tablet Fed</title>
          <description>Participants received single oral dose of 100 mg of GSK3739937 tablet under fasted condition in Treatment Period 1, followed by single oral dose of 100 mg PiB as oral suspension under moderate fed conditions in Treatment Period 2 and followed by single oral dose of 100 mg GSK3739937 tablet under fed conditions in Treatment Period 3.</description>
        </group>
        <group group_id="B18">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="4"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="9"/>
            <count group_id="B10" value="7"/>
            <count group_id="B11" value="7"/>
            <count group_id="B12" value="7"/>
            <count group_id="B13" value="3"/>
            <count group_id="B14" value="7"/>
            <count group_id="B15" value="5"/>
            <count group_id="B16" value="6"/>
            <count group_id="B17" value="6"/>
            <count group_id="B18" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>19-64</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Number of Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/Standard of care (SOC) to prevent one of the other outcomes mentioned before.</description>
        <time_frame>Up to 27 weeks</time_frame>
        <population>Safety Population included all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Number of Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/Standard of care (SOC) to prevent one of the other outcomes mentioned before.</description>
          <population>Safety Population included all randomized participants who received at least one dose of study treatment.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 - Number of Any AEs and SAEs</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before.</description>
        <time_frame>Up to 5 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
          <group group_id="O5">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 - Number of Any AEs and SAEs</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before.</description>
          <population>Safety Population</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Number of Any AEs and SAEs</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Number of Any AEs and SAEs</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before.</description>
          <population>Safety Population</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</title>
        <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</title>
          <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Giga cells per liter (10^9 cells/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.024"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="-0.02" spread="0.041"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.092"/>
                    <measurement group_id="O2" value="-0.2"/>
                    <measurement group_id="O3" value="0.02" spread="0.147"/>
                    <measurement group_id="O4" value="-0.08" spread="0.075"/>
                    <measurement group_id="O5" value="-0.02" spread="0.075"/>
                    <measurement group_id="O6" value="-0.02" spread="0.041"/>
                    <measurement group_id="O7" value="0.08" spread="0.223"/>
                    <measurement group_id="O8" value="-0.07" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.391"/>
                    <measurement group_id="O2" value="-0.5"/>
                    <measurement group_id="O3" value="0" spread="0.482"/>
                    <measurement group_id="O4" value="-0.02" spread="0.248"/>
                    <measurement group_id="O5" value="-0.13" spread="0.463"/>
                    <measurement group_id="O6" value="0.23" spread="0.339"/>
                    <measurement group_id="O7" value="0.25" spread="0.084"/>
                    <measurement group_id="O8" value="-0.22" spread="0.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.124"/>
                    <measurement group_id="O2" value="-0.1"/>
                    <measurement group_id="O3" value="0" spread="0.063"/>
                    <measurement group_id="O4" value="-0.02" spread="0.194"/>
                    <measurement group_id="O5" value="-0.03" spread="0.121"/>
                    <measurement group_id="O6" value="0.02" spread="0.133"/>
                    <measurement group_id="O7" value="0" spread="0.11"/>
                    <measurement group_id="O8" value="-0.08" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.486"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.22" spread="0.306"/>
                    <measurement group_id="O4" value="0.08" spread="1.303"/>
                    <measurement group_id="O5" value="0.03" spread="0.468"/>
                    <measurement group_id="O6" value="0.33" spread="0.48"/>
                    <measurement group_id="O7" value="0.22" spread="0.117"/>
                    <measurement group_id="O8" value="-0.03" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="26.73"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8.2" spread="25.59"/>
                    <measurement group_id="O4" value="16" spread="27.71"/>
                    <measurement group_id="O5" value="-6.3" spread="7.87"/>
                    <measurement group_id="O6" value="8.8" spread="20.5"/>
                    <measurement group_id="O7" value="13.2" spread="19.05"/>
                    <measurement group_id="O8" value="0.2" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</title>
        <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</title>
          <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.03" spread="0.049"/>
                    <measurement group_id="O4" value="-0.02" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.05"/>
                    <measurement group_id="O2" value="-0.03" spread="0.095"/>
                    <measurement group_id="O3" value="-0.01" spread="0.090"/>
                    <measurement group_id="O4" value="0.02" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.26"/>
                    <measurement group_id="O2" value="-0.07" spread="0.281"/>
                    <measurement group_id="O3" value="0.03" spread="0.427"/>
                    <measurement group_id="O4" value="0.15" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.139"/>
                    <measurement group_id="O2" value="0.04" spread="0.113"/>
                    <measurement group_id="O3" value="0.01" spread="0.135"/>
                    <measurement group_id="O4" value="-0.02" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.784"/>
                    <measurement group_id="O2" value="-0.19" spread="0.682"/>
                    <measurement group_id="O3" value="0.03" spread="0.496"/>
                    <measurement group_id="O4" value="-0.18" spread="0.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="16.24"/>
                    <measurement group_id="O2" value="-3.4" spread="18.12"/>
                    <measurement group_id="O3" value="-9.7" spread="20.11"/>
                    <measurement group_id="O4" value="-15.5" spread="32.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</title>
        <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</title>
          <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.115"/>
                    <measurement group_id="O2" value="-0.01" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.115"/>
                    <measurement group_id="O2" value="0.04" spread="0.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.058"/>
                    <measurement group_id="O2" value="0.06" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.173"/>
                    <measurement group_id="O2" value="-0.27" spread="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="47.72"/>
                    <measurement group_id="O2" value="-9.3" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</title>
        <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets</title>
          <description>Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.026"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.052"/>
                    <measurement group_id="O2" value="-0.05" spread="0.087"/>
                    <measurement group_id="O3" value="-0.05" spread="0.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.253"/>
                    <measurement group_id="O2" value="-0.08" spread="0.407"/>
                    <measurement group_id="O3" value="0.16" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.099"/>
                    <measurement group_id="O2" value="-0.01" spread="0.132"/>
                    <measurement group_id="O3" value="0.04" spread="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.703"/>
                    <measurement group_id="O2" value="-0.15" spread="1.253"/>
                    <measurement group_id="O3" value="0.17" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="15.83"/>
                    <measurement group_id="O2" value="1.5" spread="22.48"/>
                    <measurement group_id="O3" value="-6.7" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Hematology Parameters - Erythrocytes Count</title>
        <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Hematology Parameters - Erythrocytes Count</title>
          <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Trillion cells per liter (10^12 cells/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.079" spread="0.1441"/>
                    <measurement group_id="O2" value="0.17"/>
                    <measurement group_id="O3" value="0.197" spread="0.3088"/>
                    <measurement group_id="O4" value="0.245" spread="0.1623"/>
                    <measurement group_id="O5" value="0.048" spread="0.2548"/>
                    <measurement group_id="O6" value="0.11" spread="0.1368"/>
                    <measurement group_id="O7" value="0.157" spread="0.1833"/>
                    <measurement group_id="O8" value="0.182" spread="0.1526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameters - Erythrocytes Count</title>
        <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameters - Erythrocytes Count</title>
          <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.1592"/>
                    <measurement group_id="O2" value="0.017" spread="0.175"/>
                    <measurement group_id="O3" value="-0.227" spread="0.2423"/>
                    <measurement group_id="O4" value="0.037" spread="0.2601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameters - Erythrocytes Count</title>
        <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameters - Erythrocytes Count</title>
          <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.060" spread="0.2787"/>
                    <measurement group_id="O2" value="-0.014" spread="0.1021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Hematology Parameters - Erythrocytes Count</title>
        <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Hematology Parameters - Erythrocytes Count</title>
          <description>Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.229" spread="0.2193"/>
                    <measurement group_id="O2" value="0.197" spread="0.2287"/>
                    <measurement group_id="O3" value="0.189" spread="0.2014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</title>
        <description>Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</title>
          <description>Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Picogram (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.314"/>
                    <measurement group_id="O2" value="-0.5"/>
                    <measurement group_id="O3" value="0.33" spread="0.294"/>
                    <measurement group_id="O4" value="-0.08" spread="0.387"/>
                    <measurement group_id="O5" value="-0.13" spread="0.32"/>
                    <measurement group_id="O6" value="-0.13" spread="0.528"/>
                    <measurement group_id="O7" value="-0.02" spread="0.232"/>
                    <measurement group_id="O8" value="-0.03" spread="0.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</title>
        <description>Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</title>
          <description>Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Picogram (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.63"/>
                    <measurement group_id="O2" value="-0.3" spread="0.44"/>
                    <measurement group_id="O3" value="0.16" spread="0.172"/>
                    <measurement group_id="O4" value="-0.08" spread="0.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</title>
        <description>Blood samples were collected to assess change from baseline in Mean Corpuscular Hemoglobin (MCH). Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</title>
          <description>Blood samples were collected to assess change from baseline in Mean Corpuscular Hemoglobin (MCH). Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Picogram (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.666"/>
                    <measurement group_id="O2" value="-0.83" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</title>
        <description>Blood samples were collected to assess change from baseline in Mean Corpuscular Hemoglobin (MCH). Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)</title>
          <description>Blood samples were collected to assess change from baseline in Mean Corpuscular Hemoglobin (MCH). Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Picogram (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.433"/>
                    <measurement group_id="O2" value="-0.24" spread="0.487"/>
                    <measurement group_id="O3" value="0.05" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Hematology Parameter - Hematocrit</title>
        <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Hematology Parameter - Hematocrit</title>
          <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0083" spread="0.01231"/>
                    <measurement group_id="O2" value="0.014"/>
                    <measurement group_id="O3" value="0.015" spread="0.0304"/>
                    <measurement group_id="O4" value="0.0237" spread="0.01491"/>
                    <measurement group_id="O5" value="0.0012" spread="0.02409"/>
                    <measurement group_id="O6" value="0.0047" spread="0.00866"/>
                    <measurement group_id="O7" value="0.0117" spread="0.01862"/>
                    <measurement group_id="O8" value="0.0175" spread="0.01319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Hematocrit</title>
        <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Hematocrit</title>
          <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0081" spread="0.01342"/>
                    <measurement group_id="O2" value="0.0066" spread="0.01838"/>
                    <measurement group_id="O3" value="-0.0217" spread="0.01963"/>
                    <measurement group_id="O4" value="0.0043" spread="0.01929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Hematocrit</title>
        <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Hematocrit</title>
          <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0120" spread="0.02685"/>
                    <measurement group_id="O2" value="-0.0094" spread="0.00781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Hematology Parameter - Hematocrit</title>
        <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Hematology Parameter - Hematocrit</title>
          <description>Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0182" spread="0.01826"/>
                    <measurement group_id="O2" value="0.013" spread="0.02076"/>
                    <measurement group_id="O3" value="0.0159" spread="0.01793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Hematology Parameter - Reticulocytes</title>
        <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Hematology Parameter - Reticulocytes</title>
          <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Proportion of reticulocytes in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0008" spread="0.00363"/>
                    <measurement group_id="O2" value="0.002"/>
                    <measurement group_id="O3" value="-0.0045" spread="0.00622"/>
                    <measurement group_id="O4" value="-0.0008" spread="0.00264"/>
                    <measurement group_id="O5" value="-0.0007" spread="0.00234"/>
                    <measurement group_id="O6" value="-0.0015" spread="0.00302"/>
                    <measurement group_id="O7" value="-0.0008" spread="0.00194"/>
                    <measurement group_id="O8" value="-0.0008" spread="0.0016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Reticulocytes</title>
        <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Reticulocytes</title>
          <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Proportion of reticulocytes in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0017" spread="0.0024"/>
                    <measurement group_id="O2" value="-0.0011" spread="0.00219"/>
                    <measurement group_id="O3" value="0.0010" spread="0.00306"/>
                    <measurement group_id="O4" value="-0.0012" spread="0.00264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Reticulocytes</title>
        <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Reticulocytes</title>
          <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Proportion of reticulocytes in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0003" spread="0.00379"/>
                    <measurement group_id="O2" value="-0.0001" spread="0.00227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Hematology Parameter - Reticulocytes</title>
        <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Hematology Parameter - Reticulocytes</title>
          <description>Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Proportion of reticulocytes in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0011" spread="0.00231"/>
                    <measurement group_id="O2" value="-0.0009" spread="0.00255"/>
                    <measurement group_id="O3" value="-0.0012" spread="0.00224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</title>
        <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</title>
          <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="4.44"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7.5" spread="8.41"/>
                    <measurement group_id="O4" value="6.7" spread="5.2"/>
                    <measurement group_id="O5" value="1" spread="8.51"/>
                    <measurement group_id="O6" value="2.7" spread="2.73"/>
                    <measurement group_id="O7" value="4.3" spread="5.68"/>
                    <measurement group_id="O8" value="5.2" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</title>
        <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</title>
          <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="5.13"/>
                    <measurement group_id="O2" value="-1" spread="7.21"/>
                    <measurement group_id="O3" value="-5.7" spread="6.70"/>
                    <measurement group_id="O4" value="0.5" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</title>
        <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</title>
          <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="7.64"/>
                    <measurement group_id="O2" value="-4.3" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</title>
        <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)</title>
          <description>Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="5.87"/>
                    <measurement group_id="O2" value="4.5" spread="7.07"/>
                    <measurement group_id="O3" value="5.7" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Clinical Chemistry Parameter - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK)</title>
        <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Clinical Chemistry Parameter - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK)</title>
          <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>International units per Liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="6.06"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8.3" spread="4.27"/>
                    <measurement group_id="O4" value="6.7" spread="3.72"/>
                    <measurement group_id="O5" value="3" spread="3.95"/>
                    <measurement group_id="O6" value="6.2" spread="4.92"/>
                    <measurement group_id="O7" value="8.8" spread="8.04"/>
                    <measurement group_id="O8" value="6.2" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="7.78"/>
                    <measurement group_id="O2" value="-1"/>
                    <measurement group_id="O3" value="-4.2" spread="6.05"/>
                    <measurement group_id="O4" value="-0.8" spread="3.49"/>
                    <measurement group_id="O5" value="0.3" spread="9.35"/>
                    <measurement group_id="O6" value="-3.5" spread="6.32"/>
                    <measurement group_id="O7" value="1.2" spread="10.19"/>
                    <measurement group_id="O8" value="-1.3" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="6.07"/>
                    <measurement group_id="O2" value="-8"/>
                    <measurement group_id="O3" value="-4.5" spread="4.93"/>
                    <measurement group_id="O4" value="-2" spread="2.83"/>
                    <measurement group_id="O5" value="-0.5" spread="4.04"/>
                    <measurement group_id="O6" value="-3.8" spread="4.26"/>
                    <measurement group_id="O7" value="-1.8" spread="4.79"/>
                    <measurement group_id="O8" value="-1.5" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPK</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.3" spread="140.65"/>
                    <measurement group_id="O2" value="0.776"/>
                    <measurement group_id="O3" value="-0.1978" spread="0.48809"/>
                    <measurement group_id="O4" value="-0.0777" spread="0.72185"/>
                    <measurement group_id="O5" value="-0.1292" spread="0.91507"/>
                    <measurement group_id="O6" value="0.2242" spread="0.3425"/>
                    <measurement group_id="O7" value="-60.5" spread="132.53"/>
                    <measurement group_id="O8" value="-20" spread="39.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - ALT, AST, ALP and Serum CPK</title>
        <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - ALT, AST, ALP and Serum CPK</title>
          <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>International units per Liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="14.44"/>
                    <measurement group_id="O2" value="-4.6" spread="10.61"/>
                    <measurement group_id="O3" value="5.9" spread="5.34"/>
                    <measurement group_id="O4" value="3.0" spread="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="6.9"/>
                    <measurement group_id="O2" value="-5.9" spread="5.84"/>
                    <measurement group_id="O3" value="-3.9" spread="7.10"/>
                    <measurement group_id="O4" value="0.3" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="5.2"/>
                    <measurement group_id="O2" value="-7.1" spread="5.52"/>
                    <measurement group_id="O3" value="-4.1" spread="4.53"/>
                    <measurement group_id="O4" value="3.2" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPK</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="26.43"/>
                    <measurement group_id="O3" value="19.4" spread="88.50"/>
                    <measurement group_id="O4" value="14.8" spread="41.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter -ALT, AST, ALP and Serum CPK</title>
        <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter -ALT, AST, ALP and Serum CPK</title>
          <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>International units per Liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.65"/>
                    <measurement group_id="O2" value="1.9" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="7.77"/>
                    <measurement group_id="O2" value="-3.1" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="2.65"/>
                    <measurement group_id="O2" value="-3" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" spread="14.84"/>
                    <measurement group_id="O2" value="-22.6" spread="35.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Clinical Chemistry Parameter - ALT, AST, ALP and CPK</title>
        <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Clinical Chemistry Parameter - ALT, AST, ALP and CPK</title>
          <description>Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>International units per Liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="6.42"/>
                    <measurement group_id="O2" value="5.4" spread="5.91"/>
                    <measurement group_id="O3" value="5.2" spread="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="4.32"/>
                    <measurement group_id="O2" value="-0.2" spread="4.92"/>
                    <measurement group_id="O3" value="-0.4" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.67"/>
                    <measurement group_id="O2" value="0.4" spread="4.4"/>
                    <measurement group_id="O3" value="-0.9" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="52.49"/>
                    <measurement group_id="O2" value="-22.2" spread="45.6"/>
                    <measurement group_id="O3" value="-62.1" spread="73.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen, Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, Triglycerides</title>
        <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen, Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, Triglycerides</title>
          <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.46027"/>
                    <measurement group_id="O2" value="-0.499"/>
                    <measurement group_id="O3" value="-0.3147" spread="0.22689"/>
                    <measurement group_id="O4" value="-0.1387" spread="0.36972"/>
                    <measurement group_id="O5" value="-0.157" spread="0.22077"/>
                    <measurement group_id="O6" value="-0.379" spread="0.22041"/>
                    <measurement group_id="O7" value="-0.1848" spread="0.25449"/>
                    <measurement group_id="O8" value="-0.3147" spread="0.25488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.62"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1.8" spread="2.48"/>
                    <measurement group_id="O4" value="3.3" spread="3.5"/>
                    <measurement group_id="O5" value="1.7" spread="1.97"/>
                    <measurement group_id="O6" value="-0.2" spread="2.14"/>
                    <measurement group_id="O7" value="0.7" spread="2.25"/>
                    <measurement group_id="O8" value="1.3" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0693" spread="0.10417"/>
                    <measurement group_id="O2" value="-0.025"/>
                    <measurement group_id="O3" value="0.0208" spread="0.10249"/>
                    <measurement group_id="O4" value="0.1453" spread="0.04816"/>
                    <measurement group_id="O5" value="0.0707" spread="0.13915"/>
                    <measurement group_id="O6" value="0.0208" spread="0.10888"/>
                    <measurement group_id="O7" value="0.2203" spread="0.17728"/>
                    <measurement group_id="O8" value="0.0375" spread="0.05646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1294" spread="0.59228"/>
                    <measurement group_id="O2" value="0.104"/>
                    <measurement group_id="O3" value="-0.2627" spread="0.52795"/>
                    <measurement group_id="O4" value="0.444" spread="0.16643"/>
                    <measurement group_id="O5" value="-0.224" spread="0.87169"/>
                    <measurement group_id="O6" value="0.0047" spread="0.5061"/>
                    <measurement group_id="O7" value="0.1898" spread="0.3552"/>
                    <measurement group_id="O8" value="0.142" spread="0.09784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.79"/>
                    <measurement group_id="O2" value="-1"/>
                    <measurement group_id="O3" value="-0.3" spread="1.75"/>
                    <measurement group_id="O4" value="-5" spread="1.41"/>
                    <measurement group_id="O5" value="1.7" spread="1.51"/>
                    <measurement group_id="O6" value="-1.3" spread="1.51"/>
                    <measurement group_id="O7" value="-0.8" spread="1.83"/>
                    <measurement group_id="O8" value="0.3" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0187" spread="0.20182"/>
                    <measurement group_id="O2" value="0.181"/>
                    <measurement group_id="O3" value="-0.069" spread="0.20186"/>
                    <measurement group_id="O4" value="0.1247" spread="0.15293"/>
                    <measurement group_id="O5" value="-0.086" spread="0.13432"/>
                    <measurement group_id="O6" value="0.082" spread="0.11534"/>
                    <measurement group_id="O7" value="-0.0388" spread="0.30208"/>
                    <measurement group_id="O8" value="-0.043" spread="0.07956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.303"/>
                    <measurement group_id="O2" value="-0.2"/>
                    <measurement group_id="O3" value="0.18" spread="0.354"/>
                    <measurement group_id="O4" value="0.18" spread="0.293"/>
                    <measurement group_id="O5" value="0.1" spread="0.261"/>
                    <measurement group_id="O6" value="-0.28" spread="0.24"/>
                    <measurement group_id="O7" value="-0.07" spread="0.234"/>
                    <measurement group_id="O8" value="-0.12" spread="0.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0027" spread="0.44009"/>
                    <measurement group_id="O2" value="-0.078"/>
                    <measurement group_id="O3" value="-0.0605" spread="0.51701"/>
                    <measurement group_id="O4" value="0.5217" spread="0.21608"/>
                    <measurement group_id="O5" value="-0.5298" spread="0.52526"/>
                    <measurement group_id="O6" value="0.004" spread="0.35306"/>
                    <measurement group_id="O7" value="0.2023" spread="0.22274"/>
                    <measurement group_id="O8" value="-0.0388" spread="0.29351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0046" spread="0.05426"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="-0.0137" spread="0.06173"/>
                    <measurement group_id="O4" value="0.0068" spread="0.03086"/>
                    <measurement group_id="O5" value="-0.0478" spread="0.03086"/>
                    <measurement group_id="O6" value="0.0752" spread="0.06035"/>
                    <measurement group_id="O7" value="0.0342" spread="0.03086"/>
                    <measurement group_id="O8" value="0.0137" spread="0.02117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0611" spread="0.13184"/>
                    <measurement group_id="O2" value="0.097"/>
                    <measurement group_id="O3" value="0.0377" spread="0.1266"/>
                    <measurement group_id="O4" value="0.124" spread="0.13169"/>
                    <measurement group_id="O5" value="-0.0108" spread="0.16164"/>
                    <measurement group_id="O6" value="0.0052" spread="0.08782"/>
                    <measurement group_id="O7" value="0.043" spread="0.12387"/>
                    <measurement group_id="O8" value="-0.0108" spread="0.05669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1.64"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1" spread="1.26"/>
                    <measurement group_id="O4" value="0.2" spread="0.98"/>
                    <measurement group_id="O5" value="1" spread="1.26"/>
                    <measurement group_id="O6" value="-0.7" spread="1.51"/>
                    <measurement group_id="O7" value="-0.3" spread="1.37"/>
                    <measurement group_id="O8" value="2.2" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1683" spread="0.46481"/>
                    <measurement group_id="O2" value="0.18"/>
                    <measurement group_id="O3" value="-0.2225" spread="0.43845"/>
                    <measurement group_id="O4" value="0.0318" spread="0.41469"/>
                    <measurement group_id="O5" value="-0.2337" spread="0.3573"/>
                    <measurement group_id="O6" value="-0.0863" spread="0.32709"/>
                    <measurement group_id="O7" value="0.087" spread="0.12521"/>
                    <measurement group_id="O8" value="0.1467" spread="0.25766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2777" spread="0.7798"/>
                    <measurement group_id="O2" value="1.071"/>
                    <measurement group_id="O3" value="-0.4165" spread="0.79561"/>
                    <measurement group_id="O4" value="0.2975" spread="0.7629"/>
                    <measurement group_id="O5" value="-0.119" spread="0.62517"/>
                    <measurement group_id="O6" value="0.2975" spread="0.47451"/>
                    <measurement group_id="O7" value="-0.2975" spread="0.72872"/>
                    <measurement group_id="O8" value="-0.595" spread="0.29149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides</title>
        <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides</title>
          <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2773" spread="0.58989"/>
                    <measurement group_id="O2" value="-0.6027" spread="0.19341"/>
                    <measurement group_id="O3" value="0.0319" spread="0.35520"/>
                    <measurement group_id="O4" value="-0.3978" spread="0.24715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.94"/>
                    <measurement group_id="O2" value="-1.4" spread="1.4"/>
                    <measurement group_id="O3" value="-0.6" spread="2.44"/>
                    <measurement group_id="O4" value="-0.3" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0306" spread="0.14997"/>
                    <measurement group_id="O2" value="-0.2136" spread="0.12771"/>
                    <measurement group_id="O3" value="-0.0286" spread="0.08469"/>
                    <measurement group_id="O4" value="0.0373" spread="0.07016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2701" spread="0.56002"/>
                    <measurement group_id="O2" value="-0.6503" spread="0.68612"/>
                    <measurement group_id="O3" value="-0.2843" spread="0.42535"/>
                    <measurement group_id="O4" value="0.3708" spread="0.43447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.5"/>
                    <measurement group_id="O2" value="3" spread="1.15"/>
                    <measurement group_id="O3" value="-1.0" spread="1.63"/>
                    <measurement group_id="O4" value="-1.3" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1438" spread="0.15951"/>
                    <measurement group_id="O2" value="-0.1849" spread="0.13459"/>
                    <measurement group_id="O3" value="-0.0777" spread="0.14711"/>
                    <measurement group_id="O4" value="-0.0948" spread="0.21847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.44"/>
                    <measurement group_id="O2" value="-0.29" spread="0.261"/>
                    <measurement group_id="O3" value="0" spread="0.191"/>
                    <measurement group_id="O4" value="-0.22" spread="0.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2902" spread="0.38135"/>
                    <measurement group_id="O2" value="-0.5244" spread="0.48959"/>
                    <measurement group_id="O3" value="-0.2807" spread="0.30973"/>
                    <measurement group_id="O4" value="-0.0903" spread="0.86478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0547" spread="0.09168"/>
                    <measurement group_id="O2" value="-0.0996" spread="0.06635"/>
                    <measurement group_id="O3" value="-0.0527" spread="0.05659"/>
                    <measurement group_id="O4" value="-0.0205" spread="0.06737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0573" spread="0.12367"/>
                    <measurement group_id="O2" value="-0.1477" spread="0.10973"/>
                    <measurement group_id="O3" value="0.0831" spread="0.11469"/>
                    <measurement group_id="O4" value="0.0485" spread="0.09964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.67"/>
                    <measurement group_id="O2" value="1.3" spread="0.76"/>
                    <measurement group_id="O3" value="-0.9" spread="1.07"/>
                    <measurement group_id="O4" value="0.3" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0403" spread="0.20877"/>
                    <measurement group_id="O2" value="-0.1614" spread="0.26907"/>
                    <measurement group_id="O3" value="0.0434" spread="0.20744"/>
                    <measurement group_id="O4" value="0.2577" spread="0.33429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0397" spread="0.9849"/>
                    <measurement group_id="O2" value="0.408" spread="0.90851"/>
                    <measurement group_id="O3" value="-0.1020" spread="1.02466"/>
                    <measurement group_id="O4" value="0.1190" spread="0.53748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides</title>
        <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides</title>
          <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2590" spread="0.23106"/>
                    <measurement group_id="O2" value="-0.3014" spread="0.14978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.08"/>
                    <measurement group_id="O2" value="-0.3" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0913" spread="0.14160"/>
                    <measurement group_id="O2" value="-0.0391" spread="0.10029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4483" spread="0.39167"/>
                    <measurement group_id="O2" value="-0.203" spread="0.56917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.58"/>
                    <measurement group_id="O2" value="0.4" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1037" spread="0.11860"/>
                    <measurement group_id="O2" value="-0.0703" spread="0.14776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.346"/>
                    <measurement group_id="O2" value="-0.21" spread="0.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4137" spread="0.34187"/>
                    <measurement group_id="O2" value="-0.1107" spread="0.36147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0137" spread="0.02367"/>
                    <measurement group_id="O2" value="0.0059" spread="0.04981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0540" spread="0.10437"/>
                    <measurement group_id="O2" value="0.0464" spread="0.08088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.15"/>
                    <measurement group_id="O2" value="-0.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0267" spread="0.07243"/>
                    <measurement group_id="O2" value="0.0129" spread="0.25175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1190" spread="0.54533"/>
                    <measurement group_id="O2" value="0.408" spread="0.32121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides Edit Properties | Duplicate Measure</title>
        <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides Edit Properties | Duplicate Measure</title>
          <description>Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2033" spread="0.39"/>
                    <measurement group_id="O2" value="-0.3755" spread="0.24961"/>
                    <measurement group_id="O3" value="-0.2145" spread="0.27017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.96"/>
                    <measurement group_id="O2" value="0.4" spread="2.12"/>
                    <measurement group_id="O3" value="1.5" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.10971"/>
                    <measurement group_id="O2" value="0.0793" spread="0.10607"/>
                    <measurement group_id="O3" value="0.0666" spread="0.07293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1087" spread="0.30739"/>
                    <measurement group_id="O2" value="0.1218" spread="0.3317"/>
                    <measurement group_id="O3" value="0.0569" spread="0.47643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.57"/>
                    <measurement group_id="O2" value="-2.2" spread="2.14"/>
                    <measurement group_id="O3" value="-1.6" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0259" spread="0.13992"/>
                    <measurement group_id="O2" value="-0.0549" spread="0.12044"/>
                    <measurement group_id="O3" value="-0.0415" spread="0.1084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.422"/>
                    <measurement group_id="O2" value="-0.04" spread="0.361"/>
                    <measurement group_id="O3" value="-0.17" spread="0.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.219" spread="0.42617"/>
                    <measurement group_id="O2" value="0.2312" spread="0.46471"/>
                    <measurement group_id="O3" value="0.0484" spread="0.55487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0109" spread="0.07972"/>
                    <measurement group_id="O2" value="0.0217" spread="0.06338"/>
                    <measurement group_id="O3" value="0.0109" spread="0.0883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0021" spread="0.11269"/>
                    <measurement group_id="O2" value="-0.0058" spread="0.07409"/>
                    <measurement group_id="O3" value="-0.0021" spread="0.0965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.47"/>
                    <measurement group_id="O2" value="-1.1" spread="1.45"/>
                    <measurement group_id="O3" value="0.3" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1558" spread="0.44508"/>
                    <measurement group_id="O2" value="0.1801" spread="0.37021"/>
                    <measurement group_id="O3" value="0.0082" spread="0.30805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6426" spread="0.91715"/>
                    <measurement group_id="O2" value="0.504" spread="0.81856"/>
                    <measurement group_id="O3" value="0.4046" spread="1.00855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</title>
        <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</title>
          <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amylase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="17.38"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="-0.7" spread="6.12"/>
                    <measurement group_id="O4" value="-0.7" spread="4.46"/>
                    <measurement group_id="O5" value="3.7" spread="4.76"/>
                    <measurement group_id="O6" value="5.8" spread="12.02"/>
                    <measurement group_id="O7" value="-1.7" spread="11.52"/>
                    <measurement group_id="O8" value="3.7" spread="17.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="25.41"/>
                    <measurement group_id="O2" value="-31"/>
                    <measurement group_id="O3" value="-15.5" spread="25.76"/>
                    <measurement group_id="O4" value="-8" spread="20.01"/>
                    <measurement group_id="O5" value="-1.3" spread="3.93"/>
                    <measurement group_id="O6" value="3.7" spread="3.67"/>
                    <measurement group_id="O7" value="3.7" spread="4.27"/>
                    <measurement group_id="O8" value="3.8" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</title>
        <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</title>
          <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amylase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="27.96"/>
                    <measurement group_id="O2" value="-18.3" spread="17.85"/>
                    <measurement group_id="O3" value="0.3" spread="5.50"/>
                    <measurement group_id="O4" value="7.2" spread="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="22.06"/>
                    <measurement group_id="O2" value="-6.3" spread="8.62"/>
                    <measurement group_id="O3" value="1.1" spread="2.54"/>
                    <measurement group_id="O4" value="1.2" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</title>
        <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</title>
          <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amylase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="7.51"/>
                    <measurement group_id="O2" value="-10" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="5.57"/>
                    <measurement group_id="O2" value="-1.9" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</title>
        <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase</title>
          <description>Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amylase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="16.41"/>
                    <measurement group_id="O2" value="1.2" spread="12.08"/>
                    <measurement group_id="O3" value="5.1" spread="18.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="18.92"/>
                    <measurement group_id="O2" value="-0.6" spread="6.25"/>
                    <measurement group_id="O3" value="2.7" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</title>
        <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</title>
          <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Micromoles per Liter (umol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2839" spread="1.10348"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="-0.1995" spread="0.62518"/>
                    <measurement group_id="O4" value="0.4895" spread="0.46819"/>
                    <measurement group_id="O5" value="-0.285" spread="1.28724"/>
                    <measurement group_id="O6" value="0.2565" spread="1.18349"/>
                    <measurement group_id="O7" value="-0.3705" spread="0.86801"/>
                    <measurement group_id="O8" value="-0.855" spread="1.43069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="3.2598"/>
                    <measurement group_id="O2" value="-1.71"/>
                    <measurement group_id="O3" value="-0.855" spread="2.8098"/>
                    <measurement group_id="O4" value="0.57" spread="0.883"/>
                    <measurement group_id="O5" value="0.285" spread="2.5171"/>
                    <measurement group_id="O6" value="0.285" spread="2.7396"/>
                    <measurement group_id="O7" value="-1.71" spread="2.163"/>
                    <measurement group_id="O8" value="-3.135" spread="3.8109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8171" spread="5.38547"/>
                    <measurement group_id="O2" value="-8.84"/>
                    <measurement group_id="O3" value="6.188" spread="8.27379"/>
                    <measurement group_id="O4" value="6.0407" spread="3.93024"/>
                    <measurement group_id="O5" value="4.5673" spread="8.82968"/>
                    <measurement group_id="O6" value="-0.442" spread="3.65553"/>
                    <measurement group_id="O7" value="3.978" spread="4.80135"/>
                    <measurement group_id="O8" value="3.536" spread="2.56208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</title>
        <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</title>
          <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Micromoles per Liter (umol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6058" spread="1.12324"/>
                    <measurement group_id="O2" value="0.5863" spread="1.10758"/>
                    <measurement group_id="O3" value="-0.8061" spread="0.95062"/>
                    <measurement group_id="O4" value="0.2817" spread="1.28814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="3.9593"/>
                    <measurement group_id="O2" value="0.244" spread="3.6178"/>
                    <measurement group_id="O3" value="-0.977" spread="2.7674"/>
                    <measurement group_id="O4" value="1.425" spread="3.8109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.536" spread="7.48795"/>
                    <measurement group_id="O2" value="-1.768" spread="5.35289"/>
                    <measurement group_id="O3" value="-0.6314" spread="4.55680"/>
                    <measurement group_id="O4" value="8.3980" spread="2.89164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</title>
        <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</title>
          <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Micromoles per Liter (umol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5700" spread="0.98727"/>
                    <measurement group_id="O2" value="1.4671" spread="0.64254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.140" spread="2.6121"/>
                    <measurement group_id="O2" value="1.71" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1787" spread="2.55189"/>
                    <measurement group_id="O2" value="2.2731" spread="2.88068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</title>
        <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine</title>
          <description>Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Micromoles per Liter (umol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3306" spread="0.89198"/>
                    <measurement group_id="O2" value="0.4124" spread="1.068"/>
                    <measurement group_id="O3" value="0.2059" spread="1.11784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.456" spread="1.9886"/>
                    <measurement group_id="O2" value="0.905" spread="3.7813"/>
                    <measurement group_id="O3" value="1.026" spread="3.5282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0645" spread="6.90318"/>
                    <measurement group_id="O2" value="1.716" spread="6.168"/>
                    <measurement group_id="O3" value="2.9467" spread="6.70465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Clinical Chemistry Parameter - Total Protein</title>
        <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Clinical Chemistry Parameter - Total Protein</title>
          <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Grams per Liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="3.07"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4.5" spread="3.83"/>
                    <measurement group_id="O4" value="6.3" spread="3.33"/>
                    <measurement group_id="O5" value="1" spread="4.15"/>
                    <measurement group_id="O6" value="3.7" spread="2.88"/>
                    <measurement group_id="O7" value="4" spread="3.85"/>
                    <measurement group_id="O8" value="3.5" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 - (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - Total Protein</title>
        <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 - (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - Total Protein</title>
          <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Grams per Liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="3.84"/>
                    <measurement group_id="O2" value="-7.1" spread="6.26"/>
                    <measurement group_id="O3" value="-5.4" spread="3.91"/>
                    <measurement group_id="O4" value="2.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter - Total Protein</title>
        <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter - Total Protein</title>
          <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Grams per Liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="5.03"/>
                    <measurement group_id="O2" value="-2.1" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Clinical Chemistry Parameter - Total Protein</title>
        <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Clinical Chemistry Parameter - Total Protein</title>
          <description>Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Grams per Liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="5.38"/>
                    <measurement group_id="O2" value="5.4" spread="4.87"/>
                    <measurement group_id="O3" value="4.5" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Number of Participants With Abnormal Urinalysis Parameters</title>
        <description>Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.</description>
        <time_frame>Up to 27 weeks</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Number of Participants With Abnormal Urinalysis Parameters</title>
          <description>Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Occult Blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 - Number of Participants With Abnormal Urinalysis Parameters</title>
        <description>Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.</description>
        <time_frame>Up to 5 weeks</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
          <group group_id="O5">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 - Number of Participants With Abnormal Urinalysis Parameters</title>
          <description>Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Occult Blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Number of Participants With Abnormal Urinalysis Parameters</title>
        <description>Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Number of Participants With Abnormal Urinalysis Parameters</title>
          <description>Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Occult Blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
        <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
          <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="7.82"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="-0.1" spread="14.68"/>
                    <measurement group_id="O4" value="4.6" spread="7.07"/>
                    <measurement group_id="O5" value="2.3" spread="7.30"/>
                    <measurement group_id="O6" value="1.3" spread="8.04"/>
                    <measurement group_id="O7" value="2.4" spread="6.34"/>
                    <measurement group_id="O8" value="5.5" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="4.36"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="3.0" spread="8.20"/>
                    <measurement group_id="O4" value="3.7" spread="9.57"/>
                    <measurement group_id="O5" value="1.7" spread="6.15"/>
                    <measurement group_id="O6" value="-1.2" spread="4.05"/>
                    <measurement group_id="O7" value="2.7" spread="8.13"/>
                    <measurement group_id="O8" value="4.7" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
        <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
          <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="15.26"/>
                    <measurement group_id="O2" value="-2.1" spread="11.58"/>
                    <measurement group_id="O3" value="-2.1" spread="5.57"/>
                    <measurement group_id="O4" value="-0.8" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="8.73"/>
                    <measurement group_id="O2" value="0.8" spread="7.21"/>
                    <measurement group_id="O3" value="1.4" spread="5.45"/>
                    <measurement group_id="O4" value="0.0" spread="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
        <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
          <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="11.89"/>
                    <measurement group_id="O2" value="1.5" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="9.56"/>
                    <measurement group_id="O2" value="0.9" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
        <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
          <description>Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="7.20"/>
                    <measurement group_id="O2" value="3.8" spread="10.10"/>
                    <measurement group_id="O3" value="9.3" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="4.02"/>
                    <measurement group_id="O2" value="3.4" spread="8.63"/>
                    <measurement group_id="O3" value="4.4" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Vital Signs - Pulse Rate</title>
        <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Vital Signs - Pulse Rate</title>
          <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="5.03"/>
                    <measurement group_id="O2" value="15.7"/>
                    <measurement group_id="O3" value="3.5" spread="7.40"/>
                    <measurement group_id="O4" value="-0.2" spread="3.45"/>
                    <measurement group_id="O5" value="5.9" spread="2.64"/>
                    <measurement group_id="O6" value="4.8" spread="5.74"/>
                    <measurement group_id="O7" value="-0.9" spread="7.98"/>
                    <measurement group_id="O8" value="0.0" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Pulse Rate</title>
        <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Pulse Rate</title>
          <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="4.59"/>
                    <measurement group_id="O2" value="-2.8" spread="4.98"/>
                    <measurement group_id="O3" value="5.0" spread="5.49"/>
                    <measurement group_id="O4" value="3.0" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Pulse Rate</title>
        <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Pulse Rate</title>
          <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.60"/>
                    <measurement group_id="O2" value="5.2" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Vital Signs - Pulse Rate</title>
        <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Vital Signs - Pulse Rate</title>
          <description>Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="6.80"/>
                    <measurement group_id="O2" value="7.4" spread="4.98"/>
                    <measurement group_id="O3" value="6.6" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Vital Signs - Body Temperature</title>
        <description>Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Vital Signs - Body Temperature</title>
          <description>Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.320"/>
                    <measurement group_id="O2" value="-0.10"/>
                    <measurement group_id="O3" value="0.12" spread="0.248"/>
                    <measurement group_id="O4" value="-0.05" spread="0.226"/>
                    <measurement group_id="O5" value="0.10" spread="0.190"/>
                    <measurement group_id="O6" value="0.02" spread="0.117"/>
                    <measurement group_id="O7" value="0.08" spread="0.286"/>
                    <measurement group_id="O8" value="0.20" spread="0.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Body Temperature</title>
        <description>Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Body Temperature</title>
          <description>Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.283"/>
                    <measurement group_id="O2" value="-0.07" spread="0.170"/>
                    <measurement group_id="O3" value="0.09" spread="0.135"/>
                    <measurement group_id="O4" value="-0.08" spread="0.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Body Temperature</title>
        <description>Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Body Temperature</title>
          <description>Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.153"/>
                    <measurement group_id="O2" value="-0.06" spread="0.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Vital Signs - Body Temperature</title>
        <description>Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Vital Signs - Body Temperature</title>
          <description>Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.231"/>
                    <measurement group_id="O2" value="0.06" spread="0.237"/>
                    <measurement group_id="O3" value="0.15" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Change From Baseline in Vital Signs - Respiratory Rate</title>
        <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Change From Baseline in Vital Signs - Respiratory Rate</title>
          <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.97"/>
                    <measurement group_id="O2" value="-5.0"/>
                    <measurement group_id="O3" value="-3.0" spread="1.41"/>
                    <measurement group_id="O4" value="3.7" spread="1.03"/>
                    <measurement group_id="O5" value="0.7" spread="2.07"/>
                    <measurement group_id="O6" value="0.3" spread="1.51"/>
                    <measurement group_id="O7" value="0.3" spread="1.51"/>
                    <measurement group_id="O8" value="0.7" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Respiratory Rate</title>
        <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 14</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Respiratory Rate</title>
          <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.19"/>
                    <measurement group_id="O2" value="-3.4" spread="1.51"/>
                    <measurement group_id="O3" value="0.0" spread="1.63"/>
                    <measurement group_id="O4" value="1.2" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Respiratory Rate</title>
        <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 15</time_frame>
        <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Respiratory Rate</title>
          <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.00"/>
                    <measurement group_id="O2" value="-1.4" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Change From Baseline in Vital Signs - Respiratory Rate</title>
        <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, pre-dose) and Day 6</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Change From Baseline in Vital Signs - Respiratory Rate</title>
          <description>Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.03"/>
                    <measurement group_id="O2" value="-0.3" spread="2.31"/>
                    <measurement group_id="O3" value="1.2" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 - Number of Participants With Worst Case Post-Baseline Electrocardiogram (ECG) Findings</title>
        <description>Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.</description>
        <time_frame>Up to 27 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO) Single Dose</title>
            <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O8">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Number of Participants With Worst Case Post-Baseline Electrocardiogram (ECG) Findings</title>
          <description>Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 - Number of Participants With Worst Case Post-Baseline ECG Findings</title>
        <description>Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.</description>
        <time_frame>Up to 5 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PBO Once Daily (QD)</title>
            <description>Participants received once daily doses of placebo for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
          <group group_id="O5">
            <title>PBO Once Weekly (QW)</title>
            <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 - Number of Participants With Worst Case Post-Baseline ECG Findings</title>
          <description>Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Number of Participants With Worst Case Post-Baseline ECG Findings</title>
        <description>Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Number of Participants With Worst Case Post-Baseline ECG Findings</title>
          <description>Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Area Under the Plasma Concentration Time Curve (AUC) From Zero to 24 Hours (AUC[0-24]) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 12, 16 and 24 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic (PK) Population: The PK Population included all participants who undergo plasma or urine PK sampling and have evaluable PK assay results. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Area Under the Plasma Concentration Time Curve (AUC) From Zero to 24 Hours (AUC[0-24]) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic (PK) Population: The PK Population included all participants who undergo plasma or urine PK sampling and have evaluable PK assay results. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Hour*nanogram/ millilitre (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6455.362" spread="25"/>
                    <measurement group_id="O2" value="8646.757" spread="33.9"/>
                    <measurement group_id="O3" value="3522.969" spread="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mixed model was used to estimate Food Effect for the log transformed parameter AUC (0-24). Analysis was performed using fed/ fasted state and tablet/ PiB as fixed effects and participant as a random effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Square Mean Ratio</param_type>
            <param_value>2.462</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.823</ci_lower_limit>
            <ci_upper_limit>3.323</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The mixed model was used to estimate Tablet vs. PiB effect for the log transformed parameter AUC (0-24). Analysis was performed using the independent variables included a fixed effect for treatment (PiB or Tablet) and period, and participant as a random effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Square Mean Ratio</param_type>
            <param_value>1.381</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.223</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43323.02" spread="27.3"/>
                    <measurement group_id="O2" value="58892.29" spread="23.6"/>
                    <measurement group_id="O3" value="27326.99" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mixed model was used to estimate Food Effect for the log transformed parameter AUC (0-inf). Analysis was performed using fed/ fasted state and tablet/ PiB as fixed effects and participant as a random effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Square Mean Ratio</param_type>
            <param_value>2.103</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.629</ci_lower_limit>
            <ci_upper_limit>2.717</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The mixed model was used to estimate Tablet vs. PiB effect for the log transformed parameter AUC (0-inf). Analysis was performed using the independent variables included a fixed effect for treatment (PiB or Tablet) and period, and participant as a random effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Square Mean Ratio</param_type>
            <param_value>1.351</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>1.497</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3 - Maximum Observed Concentration (Cmax) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 - Maximum Observed Concentration (Cmax) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>nanogram per millilitre (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389.81" spread="23.4"/>
                    <measurement group_id="O2" value="524.99" spread="31.8"/>
                    <measurement group_id="O3" value="227.88" spread="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mixed model was used to estimate Food Effect for the log transformed parameter Cmax. Analysis was performed using fed/ fasted state and tablet/ PiB as fixed effects and participant as a random effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Square Mean Ratio</param_type>
            <param_value>2.307</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.668</ci_lower_limit>
            <ci_upper_limit>3.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The mixed model was used to estimate Tablet vs. PiB effect for the log transformed parameter Cmax. Analysis was performed using the independent variables included a fixed effect for treatment (PiB or Tablet) and period, and participant as a random effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Square Mean Ratio</param_type>
            <param_value>1.372</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>1.582</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - AUC(0-24) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12 and 24 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - AUC(0-24) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="637.8486" spread="38.8"/>
                    <measurement group_id="O2" value="1976.944" spread="24.3"/>
                    <measurement group_id="O3" value="5027.183" spread="27.4"/>
                    <measurement group_id="O4" value="9490.296" spread="15.4"/>
                    <measurement group_id="O5" value="13743.02" spread="23.6"/>
                    <measurement group_id="O6" value="23829.99" spread="53.1"/>
                    <measurement group_id="O7" value="42129.36" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - AUC From Zero (Pre-dose) to Time of the Last Quantifiable Concentration (t) (AUC [0-t]) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - AUC From Zero (Pre-dose) to Time of the Last Quantifiable Concentration (t) (AUC [0-t]) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2486.061" spread="46.4"/>
                    <measurement group_id="O2" value="11441.28" spread="31.5"/>
                    <measurement group_id="O3" value="33650.11" spread="42.5"/>
                    <measurement group_id="O4" value="64937.76" spread="18.4"/>
                    <measurement group_id="O5" value="90730.34" spread="25.9"/>
                    <measurement group_id="O6" value="158068.4" spread="70"/>
                    <measurement group_id="O7" value="293636.9" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - AUC(0-inf) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - AUC(0-inf) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">'NA' refers to not quantifiable as the GSK3739937 concentration was below the lower limit of quantification (10 ng/mL)</measurement>
                    <measurement group_id="O2" value="12788.34" spread="32.4"/>
                    <measurement group_id="O3" value="40287.05" spread="15.5"/>
                    <measurement group_id="O4" value="75181.6" spread="13.6"/>
                    <measurement group_id="O5" value="107211.7" spread="25.2"/>
                    <measurement group_id="O6" value="190803.9" spread="81.6"/>
                    <measurement group_id="O7" value="302147.5" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - Apparent Terminal Phase Half-life (T1/2) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - Apparent Terminal Phase Half-life (T1/2) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">'NA' refers to not quantifiable as the GSK3739937 concentration was below the lower limit of quantification (10 ng/mL)</measurement>
                    <measurement group_id="O2" value="75.8706" spread="7.4"/>
                    <measurement group_id="O3" value="79.0711" spread="14.4"/>
                    <measurement group_id="O4" value="91.8314" spread="13.6"/>
                    <measurement group_id="O5" value="96.7684" spread="22.7"/>
                    <measurement group_id="O6" value="82.6113" spread="9"/>
                    <measurement group_id="O7" value="67.4404" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - Apparent Oral Clearance (CL/F) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - Apparent Oral Clearance (CL/F) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>litre/ hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">'NA' refers to not quantifiable as the GSK3739937 concentration was below the lower limit of quantification (10 ng/mL)</measurement>
                    <measurement group_id="O2" value="2.3459" spread="32.4"/>
                    <measurement group_id="O3" value="1.9857" spread="15.5"/>
                    <measurement group_id="O4" value="2.1282" spread="13.6"/>
                    <measurement group_id="O5" value="2.9847" spread="25.2"/>
                    <measurement group_id="O6" value="3.3542" spread="81.6"/>
                    <measurement group_id="O7" value="2.6477" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - Cmax of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - Cmax of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.22" spread="41.6"/>
                    <measurement group_id="O2" value="127.3" spread="22.9"/>
                    <measurement group_id="O3" value="310.43" spread="21"/>
                    <measurement group_id="O4" value="528.63" spread="13.5"/>
                    <measurement group_id="O5" value="1014.31" spread="30.7"/>
                    <measurement group_id="O6" value="1458.44" spread="52"/>
                    <measurement group_id="O7" value="2863.33" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - Concentration of GSK3739937 at 24 Hours (C24) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 12, 16 and 24 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - Concentration of GSK3739937 at 24 Hours (C24) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.46" spread="37.9"/>
                    <measurement group_id="O2" value="85.3" spread="25.9"/>
                    <measurement group_id="O3" value="247.73" spread="40"/>
                    <measurement group_id="O4" value="429.55" spread="19.4"/>
                    <measurement group_id="O5" value="612.15" spread="14.6"/>
                    <measurement group_id="O6" value="1126.32" spread="71.1"/>
                    <measurement group_id="O7" value="2645.7" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - Last Quantifiable Concentration (Clast) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - Last Quantifiable Concentration (Clast) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.09" spread="31.1"/>
                    <measurement group_id="O2" value="14.41" spread="23.7"/>
                    <measurement group_id="O3" value="18.24" spread="54.1"/>
                    <measurement group_id="O4" value="39.54" spread="38.7"/>
                    <measurement group_id="O5" value="51.33" spread="70.4"/>
                    <measurement group_id="O6" value="78.7" spread="72.8"/>
                    <measurement group_id="O7" value="83.43" spread="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2 ) - Time of Occurrence of Cmax (Tmax) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2 ) - Time of Occurrence of Cmax (Tmax) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="12.1"/>
                    <measurement group_id="O3" value="7.98" lower_limit="5" upper_limit="24.1"/>
                    <measurement group_id="O4" value="7.95" lower_limit="7.95" upper_limit="24"/>
                    <measurement group_id="O5" value="6.99" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="O6" value="7" lower_limit="5" upper_limit="24.2"/>
                    <measurement group_id="O7" value="18.08" lower_limit="12.1" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - Lag Time (Tlag) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - Lag Time (Tlag) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" lower_limit="2.5" upper_limit="4.6"/>
                    <measurement group_id="O2" value="1.99" lower_limit="1.5" upper_limit="3"/>
                    <measurement group_id="O3" value="1.23" lower_limit="0.9" upper_limit="2"/>
                    <measurement group_id="O4" value="1" lower_limit="0.5" upper_limit="1.5"/>
                    <measurement group_id="O5" value="1" lower_limit="0" upper_limit="1.1"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Cohort 1 and 2) - Time to Reach Clast (Tlast) of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period.</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 Single Dose (SD) 10 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 SD 30 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 SD 80 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
          </group>
          <group group_id="O4">
            <title>GSK3739937 SD 160 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
          </group>
          <group group_id="O5">
            <title>GSK3739937 SD 320 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
          </group>
          <group group_id="O6">
            <title>GSK3739937 SD 640 mg</title>
            <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
          </group>
          <group group_id="O7">
            <title>GSK3739937 SD 800 mg</title>
            <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Cohort 1 and 2) - Time to Reach Clast (Tlast) of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="95.55" upper_limit="192.15"/>
                    <measurement group_id="O2" value="261.967" lower_limit="192.07" upper_limit="287.8"/>
                    <measurement group_id="O3" value="359.967" lower_limit="263.38" upper_limit="383.82"/>
                    <measurement group_id="O4" value="358.942" lower_limit="335.88" upper_limit="363.72"/>
                    <measurement group_id="O5" value="359.642" lower_limit="359.23" upper_limit="360.62"/>
                    <measurement group_id="O6" value="359.9" lower_limit="336.27" upper_limit="430.33"/>
                    <measurement group_id="O7" value="360.334" lower_limit="358.93" upper_limit="362.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3, 4 and 5) - AUC (0-24) of GSK3739937 on Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3, 4 and 5) - AUC (0-24) of GSK3739937 on Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1888.173" spread="24.6"/>
                    <measurement group_id="O2" value="3559.102" spread="26.3"/>
                    <measurement group_id="O3" value="5893.917" spread="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3, 4 and 5) - Cmax of GSK3739937 on Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3, 4 and 5) - Cmax of GSK3739937 on Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.12" spread="23.3"/>
                    <measurement group_id="O2" value="232.07" spread="30"/>
                    <measurement group_id="O3" value="375.26" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3, 4 and 5) - C24 of GSK3739937 on Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3, 4 and 5) - C24 of GSK3739937 on Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.33" spread="26.9"/>
                    <measurement group_id="O2" value="188.65" spread="41.1"/>
                    <measurement group_id="O3" value="271.59" spread="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3, 4 and 5) - Tmax of GSK3739937 on Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3, 4 and 5) - Tmax of GSK3739937 on Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="6" upper_limit="16"/>
                    <measurement group_id="O2" value="8" lower_limit="7" upper_limit="23.8"/>
                    <measurement group_id="O3" value="9" lower_limit="6" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3, 4 and 5) - Tlag of GSK3739937 on Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3, 4 and 5) - Tlag of GSK3739937 on Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.9" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - Tmax of GSK3739937 on Day 14</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - Tmax of GSK3739937 on Day 14</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="7.03" lower_limit="3" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - Cmax of GSK3739937 on Day 14</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - Cmax of GSK3739937 on Day 14</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766.32" spread="16"/>
                    <measurement group_id="O2" value="1149.32" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - AUC From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3739937 on Day 14</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - AUC From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3739937 on Day 14</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14592.19" spread="12.6"/>
                    <measurement group_id="O2" value="24888.49" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - Plasma Trough Concentration (Ctau) of GSK3739937 on Day 14</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - Plasma Trough Concentration (Ctau) of GSK3739937 on Day 14</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588.1557" spread="22.5"/>
                    <measurement group_id="O2" value="990.3205" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - T1/2 of GSK3739937 on Day 14</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - T1/2 of GSK3739937 on Day 14</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7725" spread="25.9"/>
                    <measurement group_id="O2" value="72.2484" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - CL/F of GSK3739937 on Day 14</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - CL/F of GSK3739937 on Day 14</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7132" spread="12.6"/>
                    <measurement group_id="O2" value="2.009" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - Tmax of GSK3739937 on Day 18</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - Tmax of GSK3739937 on Day 18</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.01" lower_limit="8.1" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - Cmax of GSK3739937 on Day 18</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - Cmax of GSK3739937 on Day 18</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2748" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - AUC From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) on Day 18</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - AUC From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) on Day 18</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58417.64" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - Plasma Trough Concentration (Ctau) of GSK3739937 on Day 18</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - Plasma Trough Concentration (Ctau) of GSK3739937 on Day 18</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2458.275" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - T1/2 of GSK3739937 on Day 18</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - T1/2 of GSK3739937 on Day 18</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5264" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - CL/F of GSK3739937 on Day 18</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - CL/F of GSK3739937 on Day 18</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Litre/ hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7118" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - AUC From Zero to 168 Hours (AUC[0-168]) of GSK3739937 From Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and up to 168 hours post-dose from Day 1</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - AUC From Zero to 168 Hours (AUC[0-168]) of GSK3739937 From Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96434.63" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Cmax of GSK3739937 on Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Cmax of GSK3739937 on Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1106.61" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Concentration of GSK3739937 at 168 Hours (C168) From Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and up to 168 hours post-dose from Day 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Concentration of GSK3739937 at 168 Hours (C168) From Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.62" spread="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Tmax of GSK3739937 on Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Tmax of GSK3739937 on Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.88" lower_limit="8" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Tlag of GSK3739937 on Day 1</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Tlag of GSK3739937 on Day 1</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6 ) - AUC(0-t) of GSK3739937 on Day 15</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6 ) - AUC(0-t) of GSK3739937 on Day 15</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169693.1" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Cmax of GSK3739937 on Day 15</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Cmax of GSK3739937 on Day 15</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1855.67" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Ctau of GSK3739937 on Day 15</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Ctau of GSK3739937 on Day 15</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455.4447" spread="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Tmax of GSK3739937 on Day 15</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Tmax of GSK3739937 on Day 15</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="9" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - T1/2 of GSK3739937 on Day 15</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - T1/2 of GSK3739937 on Day 15</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5404" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - CL/F of GSK3739937 on Day 15</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - CL/F of GSK3739937 on Day 15</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9465" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 3 (Cohort 7) - C24 of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 (Cohort 7) - C24 of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.7" spread="29.4"/>
                    <measurement group_id="O2" value="407.5" spread="39.7"/>
                    <measurement group_id="O3" value="153.97" spread="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 3 (Cohort 7) Clast of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 (Cohort 7) Clast of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.76" spread="40.8"/>
                    <measurement group_id="O2" value="25.09" spread="51.6"/>
                    <measurement group_id="O3" value="15.44" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 3 (Cohort 7) - Tmax of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 (Cohort 7) - Tmax of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="24"/>
                    <measurement group_id="O2" value="8.42" lower_limit="5" upper_limit="15.9"/>
                    <measurement group_id="O3" value="6" lower_limit="4" upper_limit="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 3 (Cohort 7) - Tlag of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 (Cohort 7) - Tlag of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 3 (Cohort 7) - Tlast of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 (Cohort 7) - Tlast of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.75" lower_limit="263.63" upper_limit="389.92"/>
                    <measurement group_id="O2" value="360.067" lower_limit="120.08" upper_limit="362.27"/>
                    <measurement group_id="O3" value="267.4" lower_limit="195.12" upper_limit="361.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 3 (Cohort 7) - T1/2 of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 (Cohort 7) - T1/2 of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7429" spread="21.5"/>
                    <measurement group_id="O2" value="72.9842" spread="17.5"/>
                    <measurement group_id="O3" value="72.8066" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 3 (Cohort 7) - CL/F of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 PiB Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 Tablet Fed</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
          </group>
          <group group_id="O3">
            <title>GSK3739937 Tablet Fasted</title>
            <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fasted conditions in each one of the three periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3 (Cohort 7) - CL/F of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3082" spread="27.3"/>
                    <measurement group_id="O2" value="1.698" spread="23.6"/>
                    <measurement group_id="O3" value="3.6594" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 - Dose Proportionality of GSK3739937 for Dose Levels 30 mg to 800 mg Using AUC(0-infinity) After Single Dose Administration of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
        <time_frame>Up to day 16</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3739937 Single Dose of 30 mg to 800 mg</title>
            <description>Participants received single dose of GSK3739937 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg in either of treatment Period 1, 2 and 3 according to randomization schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Dose Proportionality of GSK3739937 for Dose Levels 30 mg to 800 mg Using AUC(0-infinity) After Single Dose Administration of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.882" lower_limit="0.784" upper_limit="0.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 - Dose Proportionality of GSK3739937 for Dose Levels 10 mg to 800 mg Using Cmax After Single Dose Administration of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 10 mg, 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
        <time_frame>Up to day 16</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3739937 Single Dose of 10 mg to 800 mg</title>
            <description>Participants received single dose of GSK3739937 10 mg, 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg in either of treatment Period 1, 2, and 3 according to randomization schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 - Dose Proportionality of GSK3739937 for Dose Levels 10 mg to 800 mg Using Cmax After Single Dose Administration of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 10 mg, 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.914" lower_limit="0.855" upper_limit="0.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using AUC(0-24) After Repeated Dose Administration of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
        <time_frame>Up to day 33</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3739937 Repeated Dose of 25 mg to 100 mg</title>
            <description>Participants received repeated dose of GSK3739937 25 mg, 50 mg and 100 mg in treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using AUC(0-24) After Repeated Dose Administration of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.997" lower_limit="0.864" upper_limit="1.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using Cmax After Repeated Dose Administration of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
        <time_frame>Up to day 33</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3739937 Repeated Dose of 25 mg to 100 mg</title>
            <description>Participants received repeated dose of GSK3739937 25 mg, 50 mg and 100 mg in treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using Cmax After Repeated Dose Administration of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.914" lower_limit="0.777" upper_limit="1.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using Ctau After Repeated Dose Administration of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
        <time_frame>Up to day 33</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3739937 Repeated Dose of 25 mg to 100 mg</title>
            <description>Participants received repeated dose of GSK3739937 25 mg, 50 mg and 100 mg in treatment Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using Ctau After Repeated Dose Administration of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.023" lower_limit="0.878" upper_limit="1.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 AUC(0-tau) / day 1 AUC(0-tau).</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 14</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 AUC(0-tau) / day 1 AUC(0-tau).</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.728" lower_limit="6.418" upper_limit="9.305"/>
                    <measurement group_id="O2" value="6.993" lower_limit="6.025" upper_limit="8.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 18 AUC(0-tau) / day 1 AUC(0-tau).</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 18</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 18 AUC(0-tau) / day 1 AUC(0-tau).</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.943" lower_limit="6.987" upper_limit="14.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 AUC(0-tau) / day 1 AUC(0-tau).</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 AUC(0-tau) / day 1 AUC(0-tau).</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" lower_limit="1.448" upper_limit="2.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - Accumulation Ratio of Cmax (R [CMAX])</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 Cmax / day 1 Cmax.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 14</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - Accumulation Ratio of Cmax (R [CMAX])</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 Cmax / day 1 Cmax.</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="4.962" upper_limit="6.78"/>
                    <measurement group_id="O2" value="4.952" lower_limit="4.198" upper_limit="5.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - Accumulation Ratio of Cmax (R [CMAX])</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Actual measure type is Ratio. Accumulation ratio calculated as the ratio of day 18 Cmax / day 1 Cmax.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 18</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - Accumulation Ratio of Cmax (R [CMAX])</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Actual measure type is Ratio. Accumulation ratio calculated as the ratio of day 18 Cmax / day 1 Cmax.</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.325" lower_limit="5.333" upper_limit="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Accumulation Ratio of Cmax (R [CMAX])</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 Cmax / day 1 Cmax.</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Accumulation Ratio of Cmax (R [CMAX])</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 Cmax / day 1 Cmax.</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.677" lower_limit="1.381" upper_limit="2.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - Accumulation Ratio of C(Tau) (R[CTAU])</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 C(Tau) / day 1 C(Tau).</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 14</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - Accumulation Ratio of C(Tau) (R[CTAU])</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 C(Tau) / day 1 C(Tau).</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.584" lower_limit="5.256" upper_limit="8.248"/>
                    <measurement group_id="O2" value="5.25" lower_limit="4.07" upper_limit="6.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - Accumulation Ratio of C(Tau) (R[CTAU])</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 18 C(Tau) / day 1 C(Tau).</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 18</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - Accumulation Ratio of C(Tau) (R[CTAU])</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 18 C(Tau) / day 1 C(Tau).</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.133" lower_limit="5.562" upper_limit="14.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 6) - Accumulation Ratio of C(Tau) (R[CTAU])</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 C(Tau) / day 1 C(Tau).</description>
        <time_frame>Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QW 500 mg</title>
            <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 6) - Accumulation Ratio of C(Tau) (R[CTAU])</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 C(Tau) / day 1 C(Tau).</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.817" lower_limit="1.428" upper_limit="2.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 3 and 4) - Pre-dose Concentration of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. For Part 2 cohorts 3 and 4, steady-state GSK3739937 concentrations was assessed by estimating the slope of concentrations on pre-dose assessments on Days 2-14 (Part 2 cohort 3 and 4) and the day 15 (24-hr post-dose relative to dosing on day 14). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Up to day 15</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 25 mg</title>
            <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK3739937 QD 50 mg</title>
            <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 3 and 4) - Pre-dose Concentration of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. For Part 2 cohorts 3 and 4, steady-state GSK3739937 concentrations was assessed by estimating the slope of concentrations on pre-dose assessments on Days 2-14 (Part 2 cohort 3 and 4) and the day 15 (24-hr post-dose relative to dosing on day 14). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1872" lower_limit="33.0332" upper_limit="41.3412"/>
                    <measurement group_id="O2" value="57.1056" lower_limit="51.9304" upper_limit="62.2808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 (Cohort 5) - Pre-dose Concentration of GSK3739937</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. For Part 2 cohort 5, steady state GSK3739937 concentrations was assessed by estimating the slope of the concentrations of pre-dose assessments on Days 2-18 and the day 19 (24-hr post-dose relative to dosing on day 18). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Up to day 19</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3739937 QD 100 mg</title>
            <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Cohort 5) - Pre-dose Concentration of GSK3739937</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK3739937. For Part 2 cohort 5, steady state GSK3739937 concentrations was assessed by estimating the slope of the concentrations of pre-dose assessments on Days 2-18 and the day 19 (24-hr post-dose relative to dosing on day 18). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.9742" lower_limit="103.8293" upper_limit="126.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All cause mortality, Non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 27 weeks in Part 1, up to 5 weeks in Part 2 and up to 16 weeks in Part 3.</time_frame>
      <desc>Safety population included all randomized participants who received at least one dose of study treatment. Data is presented treatment-wise.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (PBO) Single Dose</title>
          <description>In Cohort 1 and 2 of Part 1, participants received single oral dose of Placebo.</description>
        </group>
        <group group_id="E2">
          <title>GSK3739937 Single Dose (SD) 10 mg</title>
          <description>In Cohort 1 of Part 1, participants received single oral dose of 10 mg GSK3739937</description>
        </group>
        <group group_id="E3">
          <title>GSK3739937 SD 30 mg</title>
          <description>In Cohort 2 of Part 1, participants received single oral dose of 30 mg GSK3739937</description>
        </group>
        <group group_id="E4">
          <title>GSK3739937 SD 80 mg</title>
          <description>In Cohort 1 of Part 1, participants received single oral dose of 80 mg GSK3739937</description>
        </group>
        <group group_id="E5">
          <title>GSK3739937 SD 160 mg</title>
          <description>In Cohort 2 of Part 1, participants received single oral dose of 160 mg GSK3739937</description>
        </group>
        <group group_id="E6">
          <title>GSK3739937 SD 320 mg</title>
          <description>In Cohort 1 of Part 1, participants received single oral dose of 320 mg GSK3739937</description>
        </group>
        <group group_id="E7">
          <title>GSK3739937 SD 640 mg</title>
          <description>In Cohort 2 of Part 1, participants received single oral dose of 640 mg GSK3739937</description>
        </group>
        <group group_id="E8">
          <title>GSK3739937 SD 800 mg</title>
          <description>In Cohort 1 of Part 1, participants received single oral dose of 800 mg of GSK3739937</description>
        </group>
        <group group_id="E9">
          <title>PBO Once Daily (QD)</title>
          <description>Participants received once daily doses of Placebo for 14 days</description>
        </group>
        <group group_id="E10">
          <title>GSK3739937 QD 25 mg</title>
          <description>In Cohort 3 of Part 2, participants received once-daily oral dose of 25 mg GSK3739937 for 14 days.</description>
        </group>
        <group group_id="E11">
          <title>GSK3739937 QD 50 mg</title>
          <description>In Cohort 4 of Part 2, participants received once-daily oral dose of 50 mg GSK3739937 for 14 days.</description>
        </group>
        <group group_id="E12">
          <title>GSK3739937 QD 100 mg</title>
          <description>In Cohort 5 of Part 2, participants received once-daily oral dose of 100 mg GSK3739937 for 18 days.</description>
        </group>
        <group group_id="E13">
          <title>PBO Once Weekly (QW)</title>
          <description>Participants received once weekly oral dose of Placebo for over 3 weeks.</description>
        </group>
        <group group_id="E14">
          <title>GSK3739937 QW 500 mg</title>
          <description>In Cohort 6 of Part 2, participants received one dose per week of 500 mg GSK3739937 for over 3 weeks.</description>
        </group>
        <group group_id="E15">
          <title>GSK3739937 PiB Fed</title>
          <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 PiB as an oral suspension under moderate fed conditions in each one of the three periods.</description>
        </group>
        <group group_id="E16">
          <title>GSK3739937 Tablet Fed</title>
          <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under moderate fed conditions in each one of the three periods.</description>
        </group>
        <group group_id="E17">
          <title>GSK3739937 Tablet Fasted</title>
          <description>In Cohort 7 of Part 3, participants received single oral dose of 100 mg of GSK3739937 Tablet under fasted conditions in each one of the three periods.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device site dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Burn oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>SARS-CoV-2 test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Premenstrual pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04493684
org study id: 212548
nct id: NCT04493684
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This study is a Phase 1, double-blind (sponsor-unblinded), randomized, placebo-controlled,
      single- and repeat-dose escalation study including a weekly oral dose (MAD) cohort and a
      relative bioavailability (RBA) and food effect (FE) cohort to investigate the safety,
      tolerability and PK of VH3739937 in healthy participants. This is a three part study. Part 1
      and Part 2 is designed to gain information on the safety, tolerability, and pharmacokinetic
      (PK) properties of GSK3739937 when administered as powder-in-a-bottle (PiB). Part 3 will
      evaluate the RBA of the GSK3739937 PiB and GSK3739937 Tablet and the safety, tolerability and
      PK parameters of the tablet formulation when administered under fasting and fed conditions.
allocation: Randomized
intervention model: Sequential Assignment
intervention model description: Part 1 is a single ascending dose study, Part 2 is multiple ascending dose study while Part 3 is a 3-period crossover design.
primary purpose: Treatment
masking: Double (Participant, Investigator)
masking description: This will be a double-blind study with participants and the site-staff blinded and sponsor unblended. Part 3 of the study will be open-label.
measure: Part 1 - Number of Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
time frame: Up to 27 weeks
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/Standard of care (SOC) to prevent one of the other outcomes mentioned before.
measure: Part 2 - Number of Any AEs and SAEs
time frame: Up to 5 weeks
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before.
measure: Part 3 - Number of Any AEs and SAEs
time frame: Up to 16 weeks
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before.
measure: Part 1 - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Hematology Parameters - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Hematology Parameters - Erythrocytes Count
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameters - Erythrocytes Count
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameters - Erythrocytes Count
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Hematology Parameters - Erythrocytes Count
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Mean Corpuscular Hemoglobin (MCH). Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Hemoglobin (MCH)
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Mean Corpuscular Hemoglobin (MCH). Blood samples were collected to assess change from baseline in Erythrocytes Mean Corpuscular Hemoglobin (MCH). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Hematology Parameter - Hematocrit
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Hematocrit
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Hematocrit
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Hematology Parameter - Hematocrit
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Hematology Parameter - Reticulocytes
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Reticulocytes
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Reticulocytes
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Hematology Parameter - Reticulocytes
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Reticulocytes. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Hematology Parameter - Hemoglobin (Hb)
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Hemoglobin (Hb). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Clinical Chemistry Parameter - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK)
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - ALT, AST, ALP and Serum CPK
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter -ALT, AST, ALP and Serum CPK
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Clinical Chemistry Parameter - ALT, AST, ALP and CPK
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP) and Serum Creatine Phosphokinase (CPK). Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen, Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, Triglycerides
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Clinical Chemistry Parameters- Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides Edit Properties | Duplicate Measure
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Potassium, Sodium, Blood Urea Nitrogen (BUN), Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and Triglycerides. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Clinical Chemistry Parameters - Amylase and Lipase
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Amylase and Lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Clinical Chemistry Parameter - Total Bilirubin, Direct Bilirubin and Creatinine
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Total Bilirubin, Direct Bilirubin and Creatinine. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Clinical Chemistry Parameter - Total Protein
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 - (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Clinical Chemistry Parameter - Total Protein
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Clinical Chemistry Parameter - Total Protein
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Clinical Chemistry Parameter - Total Protein
time frame: Baseline (Day -1) and Day 6
description: Blood samples were collected to assess change from baseline in Total Protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Number of Participants With Abnormal Urinalysis Parameters
time frame: Up to 27 weeks
description: Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.
measure: Part 2 - Number of Participants With Abnormal Urinalysis Parameters
time frame: Up to 5 weeks
description: Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.
measure: Part 3 - Number of Participants With Abnormal Urinalysis Parameters
time frame: Up to 16 weeks
description: Urine samples were collected to detect presence of occult blood and protein through dipstick and random method respectively. The results presented are worst case abnormal urinalysis results post-baseline relative to baseline.
measure: Part 1 - Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
time frame: Baseline (Day 1, pre-dose) and Day 6
description: Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Vital Signs - Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
time frame: Baseline (Day 1, pre-dose) and Day 6
description: Blood pressure (SBP and DBP) was assessed in semi-supine position with a completely automated device. Blood pressure measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Vital Signs - Pulse Rate
time frame: Baseline (Day 1, pre-dose) and Day 6
description: Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Pulse Rate
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Pulse Rate
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Vital Signs - Pulse Rate
time frame: Baseline (Day 1, pre-dose) and Day 6
description: Pulse rate was assessed in semi-supine position with a completely automated device. Pulse rate measurement preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Vital Signs - Body Temperature
time frame: Baseline (Day 1, pre-dose) and Day 6
description: Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Body Temperature
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Body Temperature
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Vital Signs - Body Temperature
time frame: Baseline (Day 1, pre-dose) and Day 6
description: Body temperature were assessed at indicated time-points. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Change From Baseline in Vital Signs - Respiratory Rate
time frame: Baseline (Day 1, pre-dose) and Day 6
description: Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QD PBO and Cohort 3, 4 and 5) - Change From Baseline in Vital Signs - Respiratory Rate
time frame: Baseline (Day 1, pre-dose) and Day 14
description: Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 2 (QW PBO and Cohort 6) - Change From Baseline in Vital Signs - Respiratory Rate
time frame: Baseline (Day 1, pre-dose) and Day 15
description: Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 3 - Change From Baseline in Vital Signs - Respiratory Rate
time frame: Baseline (Day 1, pre-dose) and Day 6
description: Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline value is presented and was calculated as post-dose visit value minus Baseline value.
measure: Part 1 - Number of Participants With Worst Case Post-Baseline Electrocardiogram (ECG) Findings
time frame: Up to 27 weeks
description: Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.
measure: Part 2 - Number of Participants With Worst Case Post-Baseline ECG Findings
time frame: Up to 5 weeks
description: Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.
measure: Part 3 - Number of Participants With Worst Case Post-Baseline ECG Findings
time frame: Up to 16 weeks
description: Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. ECG findings were categorized as Normal, Abnormal clinically significant (CS) and Abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline ECG findings have been presented.
measure: Part 3 - Area Under the Plasma Concentration Time Curve (AUC) From Zero to 24 Hours (AUC[0-24]) of GSK3739937
time frame: Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 12, 16 and 24 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 3 - AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 3 - Maximum Observed Concentration (Cmax) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - AUC(0-24) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12 and 24 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - AUC From Zero (Pre-dose) to Time of the Last Quantifiable Concentration (t) (AUC [0-t]) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - AUC(0-inf) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - Apparent Terminal Phase Half-life (T1/2) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - Apparent Oral Clearance (CL/F) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - Cmax of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - Concentration of GSK3739937 at 24 Hours (C24) of GSK3739937
time frame: Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 12, 16 and 24 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - Last Quantifiable Concentration (Clast) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2 ) - Time of Occurrence of Cmax (Tmax) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - Lag Time (Tlag) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 (Cohort 1 and 2) - Time to Reach Clast (Tlast) of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 192, 264 and 360 hours post-dose in each treatment period.
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis
measure: Part 2 (Cohort 3, 4 and 5) - AUC (0-24) of GSK3739937 on Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3, 4 and 5) - Cmax of GSK3739937 on Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3, 4 and 5) - C24 of GSK3739937 on Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3, 4 and 5) - Tmax of GSK3739937 on Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3, 4 and 5) - Tlag of GSK3739937 on Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3 and 4) - Tmax of GSK3739937 on Day 14
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3 and 4) - Cmax of GSK3739937 on Day 14
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3 and 4) - AUC From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3739937 on Day 14
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3 and 4) - Plasma Trough Concentration (Ctau) of GSK3739937 on Day 14
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3 and 4) - T1/2 of GSK3739937 on Day 14
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 3 and 4) - CL/F of GSK3739937 on Day 14
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 14
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 5) - Tmax of GSK3739937 on Day 18
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 5) - Cmax of GSK3739937 on Day 18
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 5) - AUC From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) on Day 18
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 5) - Plasma Trough Concentration (Ctau) of GSK3739937 on Day 18
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 5) - T1/2 of GSK3739937 on Day 18
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 5) - CL/F of GSK3739937 on Day 18
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 18
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - AUC From Zero to 168 Hours (AUC[0-168]) of GSK3739937 From Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and up to 168 hours post-dose from Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - Cmax of GSK3739937 on Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - Concentration of GSK3739937 at 168 Hours (C168) From Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and up to 168 hours post-dose from Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - Tmax of GSK3739937 on Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - Tlag of GSK3739937 on Day 1
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 1
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6 ) - AUC(0-t) of GSK3739937 on Day 15
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - Cmax of GSK3739937 on Day 15
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - Ctau of GSK3739937 on Day 15
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - Tmax of GSK3739937 on Day 15
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - T1/2 of GSK3739937 on Day 15
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 6) - CL/F of GSK3739937 on Day 15
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on Day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 3 (Cohort 7) - C24 of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 3 (Cohort 7) Clast of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 3 (Cohort 7) - Tmax of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 3 (Cohort 7) - Tlag of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 3 (Cohort 7) - Tlast of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 3 (Cohort 7) - T1/2 of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 3 (Cohort 7) - CL/F of GSK3739937
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 48, 72, 96, 120, 192, 264, and 360 hours post-dose in each treatment period
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 1 - Dose Proportionality of GSK3739937 for Dose Levels 30 mg to 800 mg Using AUC(0-infinity) After Single Dose Administration of GSK3739937
time frame: Up to day 16
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.
measure: Part 1 - Dose Proportionality of GSK3739937 for Dose Levels 10 mg to 800 mg Using Cmax After Single Dose Administration of GSK3739937
time frame: Up to day 16
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 10 mg, 30 mg, 80 mg, 160 mg, 320 mg, 640 mg and 800 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.
measure: Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using AUC(0-24) After Repeated Dose Administration of GSK3739937
time frame: Up to day 33
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.
measure: Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using Cmax After Repeated Dose Administration of GSK3739937
time frame: Up to day 33
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.
measure: Part 2 - Dose Proportionality of GSK3739937 for Dose Levels 25 mg to 100 mg Using Ctau After Repeated Dose Administration of GSK3739937
time frame: Up to day 33
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Dose proportionality for dose 25 mg, 50 mg and 100 mg was assessed using Power model. Log-e(dose) was fitted as fixed effect and participant was fitted as random effect. Kenward and Roger method and unstructured covariance structure was used. Slope and 90% confidence interval (CI) for the slope are presented.
measure: Part 2 (Cohort 3 and 4) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 14
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 AUC(0-tau) / day 1 AUC(0-tau).
measure: Part 2 (Cohort 5) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 18
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 18 AUC(0-tau) / day 1 AUC(0-tau).
measure: Part 2 (Cohort 6) - Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}])
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 AUC(0-tau) / day 1 AUC(0-tau).
measure: Part 2 (Cohort 3 and 4) - Accumulation Ratio of Cmax (R [CMAX])
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 14
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 Cmax / day 1 Cmax.
measure: Part 2 (Cohort 5) - Accumulation Ratio of Cmax (R [CMAX])
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 18
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Actual measure type is Ratio. Accumulation ratio calculated as the ratio of day 18 Cmax / day 1 Cmax.
measure: Part 2 (Cohort 6) - Accumulation Ratio of Cmax (R [CMAX])
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 Cmax / day 1 Cmax.
measure: Part 2 (Cohort 3 and 4) - Accumulation Ratio of C(Tau) (R[CTAU])
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 14
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 14 C(Tau) / day 1 C(Tau).
measure: Part 2 (Cohort 5) - Accumulation Ratio of C(Tau) (R[CTAU])
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 18
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 18 C(Tau) / day 1 C(Tau).
measure: Part 2 (Cohort 6) - Accumulation Ratio of C(Tau) (R[CTAU])
time frame: Pre-dose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 16 hours post-dose on both Day 1 and Day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. PK parameters were analyzed using standard non-compartmental analysis. Accumulation ratio calculated as the ratio of day 15 C(Tau) / day 1 C(Tau).
measure: Part 2 (Cohort 3 and 4) - Pre-dose Concentration of GSK3739937
time frame: Up to day 15
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. For Part 2 cohorts 3 and 4, steady-state GSK3739937 concentrations was assessed by estimating the slope of concentrations on pre-dose assessments on Days 2-14 (Part 2 cohort 3 and 4) and the day 15 (24-hr post-dose relative to dosing on day 14). PK parameters were analyzed using standard non-compartmental analysis.
measure: Part 2 (Cohort 5) - Pre-dose Concentration of GSK3739937
time frame: Up to day 19
description: Blood samples were collected at indicated time points for PK analysis of GSK3739937. For Part 2 cohort 5, steady state GSK3739937 concentrations was assessed by estimating the slope of the concentrations of pre-dose assessments on Days 2-18 and the day 19 (24-hr post-dose relative to dosing on day 18). PK parameters were analyzed using standard non-compartmental analysis.
arm group label: Part 1: Cohort 1: Participants receiving GSK3739937
arm group type: Experimental
description: Part 1 cohort 1 may contain up to 4 escalating doses (Period 1- 10 milligram [mg], Period 2- 80 mg, and Period 3- 320 mg, Period 4- 800 mg) of GSK3739937.
arm group label: Part 1: Cohort 1: Participants receiving Placebo
arm group type: Placebo Comparator
description: In this cohort, participants will be randomized to receive placebo.
arm group label: Part 1: Cohort 2: Participants receiving GSK3739937
arm group type: Experimental
description: Part 1 cohort 2 may contain up to 3 escalating doses ( Period 1- 30 mg, Period 2- 160 mg, and Period 3- 640 mg) of GSK3739937.
arm group label: Part 1: Cohort 2: Participants receiving Placebo
arm group type: Placebo Comparator
description: In this cohort, participants will be randomized to receive placebo.
arm group label: Part 2: Cohort 3: Participants receiving GSK3739937
arm group type: Experimental
description: Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 25 mg GSK3739937 for 14 days.
arm group label: Part 2: Cohort 3: Participants receiving Placebo
arm group type: Placebo Comparator
description: Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
arm group label: Part 2: Cohort 4: Participants receiving GSK3739937
arm group type: Experimental
description: Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 50 mg GSK3739937 for 14 days.
arm group label: Part 2: Cohort 4: Participants receiving Placebo
arm group type: Placebo Comparator
description: Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
arm group label: Part 2: Cohort 5: Participants receiving GSK3739937
arm group type: Experimental
description: Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 100 mg GSK3739937 for 18 days.
arm group label: Part 2: Cohort 5: Participants receiving placebo
arm group type: Placebo Comparator
description: Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 18 days.
arm group label: Part 2: Cohort 6: Participants receiving GSK3739937
arm group type: Experimental
description: Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 7 participants will be randomized to receive three 500 mg doses of GSK3739937 administered at once weekly intervals over two weeks.
arm group label: Part 2: Cohort 6: Participants receiving placebo
arm group type: Placebo Comparator
description: Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 3 participants will be randomized to receive three doses of placebo administered at once weekly intervals over two weeks.
arm group label: Part 3: Cohort 7: Participants receiving treatment sequence ABC
arm group type: Experimental
description: Participants will receive Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 1; Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 2; and Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 3.
arm group label: Part 3: Cohort 7: Participants receiving treatment sequence BCA
arm group type: Experimental
description: Participants will receive Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 1; Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 2; and Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 3.
arm group label: Part 3: Cohort 7: Participants receiving treatment sequence CAB
arm group type: Experimental
description: Participants will receive Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 1; Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 2; and Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 3.
intervention type: Drug
intervention name: GSK3739937 (PIB)
description: GSK3739937 will be administered as oral suspension.
arm group label: Part 1: Cohort 1: Participants receiving GSK3739937
arm group label: Part 1: Cohort 2: Participants receiving GSK3739937
arm group label: Part 2: Cohort 3: Participants receiving GSK3739937
arm group label: Part 2: Cohort 4: Participants receiving GSK3739937
arm group label: Part 2: Cohort 5: Participants receiving GSK3739937
arm group label: Part 2: Cohort 6: Participants receiving GSK3739937
arm group label: Part 3: Cohort 7: Participants receiving treatment sequence ABC
arm group label: Part 3: Cohort 7: Participants receiving treatment sequence BCA
arm group label: Part 3: Cohort 7: Participants receiving treatment sequence CAB
intervention type: Drug
intervention name: Placebo
description: Placebo will be given orally during each dosing day.
arm group label: Part 1: Cohort 1: Participants receiving Placebo
arm group label: Part 1: Cohort 2: Participants receiving Placebo
arm group label: Part 2: Cohort 3: Participants receiving Placebo
arm group label: Part 2: Cohort 4: Participants receiving Placebo
arm group label: Part 2: Cohort 5: Participants receiving placebo
arm group label: Part 2: Cohort 6: Participants receiving placebo
intervention type: Drug
intervention name: GSK3739937 (Tablet)
description: GSK3739937 Tablet will be administered via oral route.
arm group label: Part 3: Cohort 7: Participants receiving treatment sequence ABC
arm group label: Part 3: Cohort 7: Participants receiving treatment sequence BCA
arm group label: Part 3: Cohort 7: Participants receiving treatment sequence CAB
criteria: 
gender: All
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: ViiV Healthcare
facility: 
country: United States
responsible party type: Sponsor
mesh term: HIV Infections
sharing ipd: Yes
ipd description: IPD for this study will be made available via the Clinical Study Data Request site.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd info type: Clinical Study Report (CSR)
ipd time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
ipd access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
ipd url: http://clinicalstudydatarequest.com
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 